Tables | Volume 26 Number 2 | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1a. Stage of Disease at Time of HIV Diagnosis During 2019 Among Persons Aged ≥13 Years, by Selected Characteristics—44 States and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Gender
Male	26,827	2,237	8.3	6,659	24.8	8,426	31.4	5,449	20.3	4,056	15.1
Female	6,322	355	5.6	1,877	29.7	1,770	28.0	1,293	20.5	1,027	16.2
Transgender male-to-female^c	584	54	9.2	196	33.6	162	27.7	84	14.4	88	15.1
Transgender female-to-male^c	45	6	13.3	17	37.8	14	31.1	4	8.9	4	8.9
Additional gender identity^d	17	4	23.5	8	47.1	4	23.5	0	0.0	1	5.9
Age at diagnosis (yr)
13–24	7,093	791	11.2	1,971	27.8	2,567	36.2	593	8.4	1,171	16.5
25–34	12,105	1,004	8.3	3,318	27.4	3,897	32.2	1,972	16.3	1,914	15.8
35–44	6,560	425	6.5	1,747	26.6	1,821	27.8	1,640	25.0	927	14.1
45–54	4,523	246	5.4	1,010	22.3	1,178	26.0	1,417	31.3	672	14.9
≥55	3,514	190	5.4	711	20.2	913	26.0	1,208	34.4	492	14.0
Race/ethnicity
American Indian/Alaska Native	206	21	10.2	61	29.6	68	33.0	26	12.6	30	14.6
Asian	687	49	7.1	137	19.9	234	34.1	169	24.6	98	14.3
Black/African American	14,268	1,062	7.4	3,430	24.0	4,421	31.0	2,759	19.3	2,596	18.2
Hispanic/Latino^e	9,478	782	8.3	2,436	25.7	3,126	33.0	2,002	21.1	1,132	11.9
Native Hawaiian/other Pacific Islander	66	8	12.1	12	18.2	22	33.3	11	16.7	13	19.7
White	8,249	658	8.0	2,443	29.6	2,256	27.3	1,706	20.7	1,186	14.4
Multiracial	841	76	9.0	238	28.3	249	29.6	157	18.7	121	14.4
Transmission category^f
Male-to-male sexual contact	22,392	1,985	8.9	5,681	25.4	7,219	32.2	4,196	18.7	3,310	14.8
Injection drug use	2,175	137	6.3	570	26.2	559	25.7	479	22.0	429	19.7
Male	1,190	68	5.7	265	22.3	325	27.3	302	25.4	231	19.4
Female	985	70	7.1	305	31.0	234	23.8	177	18.0	198	20.1
Male-to-male sexual contact and injection drug use	1,347	126	9.4	450	33.4	357	26.5	224	16.6	190	14.1
Heterosexual contact^g	7,821	405	5.2	2,042	26.1	2,223	28.4	1,912	24.4	1,239	15.8
Male	2,459	114	4.6	460	18.7	679	27.6	798	32.5	408	16.6
Female	5,362	291	5.4	1,582	29.5	1,544	28.8	1,114	20.8	831	15.5
Total^h	33,795	2,656	7.9	8,757	25.9	10,376	30.7	6,830	20.2	5,176	15.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.
^c“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^dAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1b. Stage of disease at time of HIV diagnosis during 2019 among persons aged ≥13 years, by area of residence—44 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Alabama	638	40	6.3	146	22.9	206	32.3	139	21.8	107	16.8
Alaska	27	2	7.4	12	44.4	7	25.9	2	7.4	4	14.8
Arizona	761	45	5.9	222	29.2	266	35.0	133	17.5	95	12.5
Arkansas	287	11	3.8	76	26.5	73	25.4	72	25.1	55	19.2
California	4,354	411	9.4	1,177	27.0	1,373	31.5	818	18.8	575	13.2
Colorado	461	22	4.8	133	28.9	150	32.5	102	22.1	54	11.7
Connecticut	213	21	9.9	51	23.9	64	30.0	60	28.2	17	8.0
Delaware	93	4	4.3	23	24.7	30	32.3	20	21.5	16	17.2
District of Columbia	255	20	7.8	70	27.5	86	33.7	37	14.5	42	16.5
Florida	4,378	268	6.1	1,278	29.2	1,328	30.3	917	20.9	587	13.4
Georgia	2,439	97	4.0	656	26.9	805	33.0	493	20.2	388	15.9
Hawaii	65	5	7.7	18	27.7	23	35.4	13	20.0	6	9.2
Illinois	1,252	74	5.9	288	23.0	388	31.0	236	18.8	266	21.2
Indiana	486	13	2.7	110	22.6	120	24.7	100	20.6	143	29.4
Iowa	100	50	50.0	15	15.0	9	9.0	21	21.0	5	5.0
Louisiana	881	95	10.8	206	23.4	284	32.2	186	21.1	110	12.5
Maine	30	0	0.0	3	10.0	13	43.3	11	36.7	3	10.0
Maryland	918	97	10.6	208	22.7	293	31.9	208	22.7	112	12.2
Massachusetts	535	28	5.2	176	32.9	172	32.1	109	20.4	50	9.3
Michigan	674	53	7.9	186	27.6	227	33.7	148	22.0	60	8.9
Minnesota	274	18	6.6	67	24.5	96	35.0	63	23.0	30	10.9
Mississippi	477	11	2.3	86	18.0	96	20.1	120	25.2	164	34.4
Missouri	488	20	4.1	118	24.2	148	30.3	89	18.2	113	23.2
Montana	25	2	8.0	6	24.0	9	36.0	4	16.0	4	16.0
Nebraska	81	1	1.2	22	27.2	24	29.6	21	25.9	13	16.0
Nevada	512	28	5.5	132	25.8	125	24.4	114	22.3	113	22.1
New Hampshire	31	2	6.5	5	16.1	13	41.9	4	12.9	7	22.6
New Mexico	156	8	5.1	40	25.6	51	32.7	24	15.4	33	21.2
New York	2,330	284	12.2	558	23.9	780	33.5	496	21.3	212	9.1
North Carolina	1,365	162	11.9	312	22.9	370	27.1	213	15.6	308	22.6
North Dakota	40	1	2.5	13	32.5	15	37.5	9	22.5	2	5.0
Ohio	980	21	2.1	245	25.0	348	35.5	209	21.3	157	16.0
Oklahoma	320	19	5.9	73	22.8	74	23.1	50	15.6	104	32.5
Oregon	199	36	18.1	48	24.1	50	25.1	49	24.6	16	8.0
Rhode Island	72	10	13.9	19	26.4	18	25.0	14	19.4	11	15.3
South Carolina	680	53	7.8	182	26.8	235	34.6	164	24.1	46	6.8
South Dakota	33	2	6.1	6	18.2	12	36.4	8	24.2	5	15.2
Tennessee	773	34	4.4	222	28.7	219	28.3	134	17.3	164	21.2
Texas	4,302	428	9.9	1,061	24.7	1,244	28.9	842	19.6	727	16.9
Utah	135	11	8.1	42	31.1	39	28.9	27	20.0	16	11.9
Virginia	822	73	8.9	186	22.6	248	30.2	168	20.4	147	17.9
Washington	483	50	10.4	150	31.1	137	28.4	106	21.9	40	8.3
West Virginia	146	5	3.4	53	36.3	31	21.2	23	15.8	34	23.3
Wisconsin	211	21	10.0	53	25.1	70	33.2	52	24.6	15	7.1
Wyoming	13	0	0.0	4	30.8	7	53.8	2	15.4	0	0.0
Total	33,795	2,656	7.9	8,757	25.9	10,376	30.7	6,830	20.2	5,176	15.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.

Table 1c. Stage of disease at time of HIV diagnosis during 2019 among persons aged ≥13 years, by race/ethnicity and selected characteristics—44 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	157	18	11.5	48	30.6	50	31.8	17	10.8	24	15.3
Female	44	2	4.5	11	25.0	17	38.6	8	18.2	6	13.6
Transgender male-to-female^c	5	1	20.0	2	40.0	1	20.0	1	20.0	0	0.0
Transgender female-to-male^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	46	3	6.5	15	32.6	24	52.2	2	4.3	2	4.3
25–34	63	6	9.5	20	31.7	23	36.5	5	7.9	9	14.3
35–44	57	6	10.5	17	29.8	15	26.3	9	15.8	10	17.5
45–54	27	4	14.8	7	25.9	3	11.1	7	25.9	6	22.2
≥55	13	2	15.4	2	15.4	3	23.1	3	23.1	3	23.1
Transmission category^e
Male-to-male sexual contact	123	17	13.5	41	33.4	38	31.0	11	8.7	17	13.4
Injection drug use
Male	15	2	14.3	2	15.6	6	40.9	2	11.0	3	18.2
Female	18	1	5.7	3	14.3	7	41.7	3	18.9	3	19.4
Male-to-male sexual contact and injection drug use	15	0	0.7	4	29.1	4	27.7	4	27.7	2	14.9
Heterosexual contact^f
Male	8	0	0.0	2	24.1	2	28.9	1	16.9	3	30.1
Female	27	1	3.8	9	32.1	10	36.6	5	17.7	3	9.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	107	12	11.2	33	30.8	32	29.9	14	13.1	16	15.0
Metropolitan areas (pop. 50,000–499,999)	32	3	9.4	11	34.4	13	40.6	2	6.3	3	9.4
Nonmetropolitan areas (pop. <50,000)	63	6	9.5	16	25.4	23	36.5	8	12.7	10	15.9
Total	206	21	10.2	61	29.6	68	33.0	26	12.6	30	14.6
Asian
Gender
Male	583	46	7.9	118	20.2	194	33.3	144	24.7	81	13.9
Female	92	3	3.3	18	19.6	34	37.0	21	22.8	16	17.4
Transgender male-to-female^c	11	0	0.0	1	9.1	5	45.5	4	36.4	1	9.1
Transgender female-to-male^c	1	0	0.0	0	0.0	1	100	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	120	14	11.7	27	22.5	48	40.0	14	11.7	17	14.2
25–34	251	25	10.0	56	22.3	79	31.5	59	23.5	32	12.7
35–44	143	6	4.2	31	21.7	47	32.9	38	26.6	21	14.7
45–54	112	2	1.8	15	13.4	41	36.6	37	33.0	17	15.2
≥55	61	2	3.3	8	13.1	19	31.1	21	34.4	11	18.0
Transmission category^e
Male-to-male sexual contact	539	44	8.2	112	20.8	184	34.2	126	23.4	73	13.5
Injection drug use
Male	12	0	0.0	1	10.5	4	29.0	5	38.7	3	21.8
Female	6	0	4.8	1	19.4	2	32.3	2	27.4	1	16.1
Male-to-male sexual contact and injection drug use	13	1	7.9	0	3.2	2	17.5	6	50.0	3	21.4
Heterosexual contact^f
Male	27	1	3.8	4	13.9	9	33.1	10	39.1	3	10.2
Female	86	3	3.0	17	19.4	33	38.2	19	22.1	15	17.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	615	45	7.3	121	19.7	214	34.8	151	24.6	84	13.7
Metropolitan areas (pop. 50,000–499,999)	51	2	3.9	13	25.5	16	31.4	12	23.5	8	15.7
Nonmetropolitan areas (pop. <50,000)	15	2	13.3	1	6.7	3	20.0	5	33.3	4	26.7
Total	687	49	7.1	137	19.9	234	34.1	169	24.6	98	14.3
Black/African American
Gender
Male	10,478	859	8.2	2,324	22.2	3,357	32.0	1,995	19.0	1,943	18.5
Female	3,498	177	5.1	1,004	28.7	983	28.1	734	21.0	600	17.2
Transgender male-to-female^c	269	21	7.8	92	34.2	78	29.0	28	10.4	50	18.6
Transgender female-to-male^c	19	4	21.1	8	42.1	3	15.8	2	10.5	2	10.5
Additional gender identity^d	4	1	25.0	2	50.0	0	0.0	0	0.0	1	25.0
Age at diagnosis (yr)
13–24	3,650	411	11.3	928	25.4	1,317	36.1	311	8.5	683	18.7
25–34	5,025	401	8.0	1,258	25.0	1,602	31.9	796	15.8	968	19.3
35–44	2,393	120	5.0	566	23.7	662	27.7	635	26.5	410	17.1
45–54	1,676	70	4.2	354	21.1	442	26.4	524	31.3	286	17.1
≥55	1,524	60	3.9	324	21.3	398	26.1	493	32.3	249	16.3
Transmission category^e
Male-to-male sexual contact	8,571	764	8.9	2,008	23.4	2,834	33.1	1,414	16.5	1,551	18.1
Injection drug use
Male	360	22	6.0	67	18.6	91	25.3	95	26.4	85	23.6
Female	277	18	6.5	69	24.8	63	22.7	71	25.6	57	20.4
Male-to-male sexual contact and injection drug use	274	24	8.7	75	27.4	81	29.7	41	15.0	53	19.2
Heterosexual contact^f
Male	1,528	71	4.7	265	17.4	425	27.8	465	30.4	302	19.8
Female	3,226	163	5.0	939	29.1	919	28.5	661	20.5	544	16.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	11,265	853	7.6	2,766	24.6	3,488	31.0	2,107	18.7	2,051	18.2
Metropolitan areas (pop. 50,000–499,999)	1,777	135	7.6	402	22.6	570	32.1	375	21.1	295	16.6
Nonmetropolitan areas (pop. <50,000)	867	44	5.1	187	21.6	260	30.0	208	24.0	168	19.4
Total	14,268	1,062	7.4	3,430	24.0	4,421	31.0	2,759	19.3	2,596	18.2

Hispanic/Latino^g
Gender
Male	8,116	681	8.4	2,031	25.0	2,724	33.6	1,712	21.1	968	11.9
Female	1,136	69	6.1	333	29.3	340	29.9	253	22.3	141	12.4
Transgender male-to-femalec	211	29	13.7	66	31.3	58	27.5	36	17.1	22	10.4
Transgender female-to-malec	11	1	9.1	4	36.4	4	36.4	1	9.1	1	9.1
Additional gender identityd	4	2	50.0	2	50.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	1,974	225	11.4	559	28.3	756	38.3	174	8.8	260	13.2
25–34	3,632	297	8.2	987	27.2	1,273	35.0	655	18.0	420	11.6
35–44	2,051	148	7.2	521	25.4	596	29.1	563	27.5	223	10.9
45–54	1,179	79	6.7	260	22.1	318	27.0	366	31.0	156	13.2
≥55	642	33	5.1	109	17.0	183	28.5	244	38.0	73	11.4
Transmission category^e
Male-to-male sexual contact	7,196	636	8.8	1,816	25.2	2,472	34.3	1,415	19.7	857	11.9
Injection drug use
Male	263	19	7.3	60	22.9	69	26.2	75	28.6	40	15.0
Female	156	14	9.0	44	27.9	41	26.4	32	20.8	25	15.9
Male-to-male sexual contact and injection drug use	373	35	9.4	124	33.2	100	26.7	72	19.2	43	11.4
Heterosexual contact^f
Male	489	20	4.1	98	19.9	138	28.1	184	37.6	50	10.2
Female	988	57	5.7	292	29.6	301	30.5	221	22.4	117	11.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,263	689	8.3	2,135	25.8	2,743	33.2	1,735	21.0	961	11.6
Metropolitan areas (pop. 50,000–499,999)	800	78	9.8	188	23.5	257	32.1	172	21.5	105	13.1
Nonmetropolitan areas (pop. <50,000)	327	9	2.8	93	28.4	101	30.9	78	23.9	46	14.1
Total	9,478	782	8.3	2,436	25.7	3,126	33.0	2,002	21.1	1,132	11.9
Native Hawaiian/other Pacific Islander
Gender
Male	52	7	13.5	8	15.4	19	36.5	7	13.5	11	21.2
Female	9	1	11.1	3	33.3	2	22.2	2	22.2	1	11.1
Transgender male-to-female^c	5	0	0.0	1	20.0	1	20.0	2	40.0	1	20.0
Transgender female-to-male^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	10	3	30.0	4	40.0	2	20.0	0	0.0	1	10.0
25–34	35	2	5.7	4	11.4	16	45.7	5	14.3	8	22.9
35–44	14	2	14.3	4	28.6	3	21.4	3	21.4	2	14.3
45–54	5	1	20.0	0	0.0	1	20.0	3	60.0	0	0.0
≥55	2	0	0.0	0	0.0	0	0.0	0	0.0	2	100
Transmission category^e
Male-to-male sexual contact	52	7	13.4	9	17.1	19	36.3	7	12.9	11	20.3
Injection drug use
Male	1	0	0.0	0	0.0	0	0.0	0	8.3	1	91.7
Female	0	0	0.0	0	33.3	0	0.0	0	66.7	0	0.0
Male-to-male sexual contact and injection drug use	2	0	0.0	0	4.8	0	0.0	2	95.2	0	0.0
Heterosexual contact^f
Male	2	0	0.0	0	0.0	1	73.3	0	13.3	0	13.3
Female	9	1	11.5	3	33.3	2	23.0	2	20.7	1	11.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	51	6	11.8	8	15.7	19	37.3	8	15.7	10	19.6
Metropolitan areas (pop. 50,000–499,999)	11	0	0.0	4	36.4	3	27.3	2	18.2	2	18.2
Nonmetropolitan areas (pop. <50,000)	4	2	50.0	0	0.0	0	0.0	1	25.0	1	25.0
Total	66	8	12.1	12	18.2	22	33.3	11	16.7	13	19.7
White
Gender
Male	6,805	565	8.3	1,960	28.8	1,890	27.8	1,456	21.4	934	13.7
Female	1,357	88	6.5	449	33.1	341	25.1	239	17.6	240	17.7
Transgender male-to-female^c	71	3	4.2	29	40.8	18	25.4	10	14.1	11	15.5
Transgender female-to-male^c	11	1	9.1	3	27.3	5	45.5	1	9.1	1	9.1
Additional gender identity^d	5	1	20.0	2	40.0	2	40.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	1,107	115	10.4	379	34.2	365	33.0	75	6.8	173	15.6
25–34	2,759	236	8.6	895	32.4	792	28.7	409	14.8	427	15.5
35–44	1,749	135	7.7	555	31.7	458	26.2	359	20.5	242	13.8
45–54	1,431	85	5.9	356	24.9	349	24.4	444	31.0	197	13.8
≥55	1,203	87	7.2	258	21.4	292	24.3	419	34.8	147	12.2
Transmission category^e
Male-to-male sexual contact	5,376	462	8.6	1,550	28.8	1,507	28.0	1,134	21.1	722	13.4
Injection drug use
Male	513	24	4.7	127	24.7	148	29.0	117	22.9	96	18.7
Female	490	32	6.6	177	36.0	113	23.1	64	13.0	104	21.3
Male-to-male sexual contact and injection drug use	622	62	10.0	231	37.1	159	25.5	90	14.5	80	12.9
Heterosexual contact^f
Male	363	20	5.6	82	22.5	93	25.7	122	33.5	46	12.6
Female	875	56	6.4	275	31.5	232	26.5	175	20.0	136	15.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	5,959	517	8.7	1,806	30.3	1,661	27.9	1,147	19.2	828	13.9
Metropolitan areas (pop. 50,000–499,999)	1,365	86	6.3	394	28.9	364	26.7	323	23.7	198	14.5
Nonmetropolitan areas (pop. <50,000)	805	44	5.5	209	26.0	199	24.7	222	27.6	131	16.3
Total	8,249	658	8.0	2,443	29.6	2,256	27.3	1,706	20.7	1,186	14.4
Multiracial
Gender
Male	636	61	9.6	170	26.7	192	30.2	118	18.6	95	14.9
Female	186	15	8.1	59	31.7	53	28.5	36	19.4	23	12.4
Transgender male-to-female^c	12	0	0.0	5	41.7	1	8.3	3	25.0	3	25.0
Transgender female-to-male^c	3	0	0.0	2	66.7	1	33.3	0	0.0	0	0.0
Additional gender identity^d	4	0	0.0	2	50.0	2	50.0	0	0.0	0	0.0
Age at diagnosis (yr)
13–24	186	20	10.8	59	31.7	55	29.6	17	9.1	35	18.8
25–34	340	37	10.9	98	28.8	112	32.9	43	12.6	50	14.7
35–44	153	8	5.2	53	34.6	40	26.1	33	21.6	19	12.4
45–54	93	5	5.4	18	19.4	24	25.8	36	38.7	10	10.8
≥55	69	6	8.7	10	14.5	18	26.1	28	40.6	7	10.1
Transmission category^e
Male-to-male sexual contact	534	55	10.3	145	27.1	165	30.9	89	16.7	80	15.0
Injection drug use
Male	25	0	0.4	7	29.6	6	25.5	8	30.4	4	14.2
Female	38	4	11.7	13	33.6	8	20.3	5	13.3	8	21.1
Male-to-male sexual contact and injection drug use	49	4	8.8	15	31.2	11	22.8	8	16.9	10	20.4
Heterosexual contact^f
Male	42	2	3.5	10	22.6	11	26.2	16	37.3	4	10.4
Female	152	11	7.0	48	31.7	47	31.1	31	20.3	15	9.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	669	59	8.8	188	28.1	193	28.8	130	19.4	99	14.8
Metropolitan areas (pop. 50,000–499,999)	110	13	11.8	34	30.9	35	31.8	15	13.6	13	11.8
Nonmetropolitan areas (pop. <50,000)	52	3	5.8	13	25.0	16	30.8	12	23.1	8	15.4
Total	841	76	9.0	238	28.3	249	29.6	157	18.7	121	14.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.
^c“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^dAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^eData have been statistically adjusted to account for missing transmission category; therefore, valuesmay not sum to column total. Data presented based on sex at birth and include transgender persons.
^fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^gHispanic/Latino persons can be of any race.

Table 1d. Stage of disease at time of HIV diagnosis during 2019 among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—44 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	33	2	6.1	12	35.6	18	53.2	0	0.0	2	5.2
25–34	45	6	13.0	15	32.9	14	31.8	4	8.1	6	14.3
35–44	25	4	15.7	11	43.3	3	11.8	4	15.0	4	14.2
45–54	14	3	21.0	3	21.7	2	14.5	3	21.7	3	21.0
≥55	7	2	30.8	1	12.3	2	23.1	0	4.6	2	29.2
Asian
13–24	107	12	11.2	23	21.4	44	41.1	12	11.6	16	14.7
25–34	210	24	11.4	49	23.2	64	30.3	46	22.0	28	13.1
35–44	111	6	5.4	24	21.9	38	33.8	28	25.5	15	13.3
45–54	80	1	1.2	12	14.7	32	39.4	26	32.5	10	12.2
≥55	30	1	3.3	4	13.8	7	24.0	13	42.1	5	16.8
Black/African American
13–24	2,948	352	11.9	712	24.2	1,103	37.4	243	8.3	538	18.2
25–34	3,523	301	8.5	862	24.5	1,159	32.9	542	15.4	659	18.7
35–44	1,141	70	6.1	257	22.5	308	27.0	312	27.3	195	17.1
45–54	585	27	4.6	106	18.2	159	27.1	191	32.7	102	17.5
≥55	373	15	3.9	71	18.9	106	28.4	126	33.8	56	15.0
Hispanic/Latino^c
13–24	1,678	199	11.9	459	27.3	653	38.9	147	8.8	220	13.1
25–34	2,939	251	8.5	771	26.2	1,063	36.2	521	17.7	334	11.3
35–44	1,461	114	7.8	362	24.8	432	29.5	385	26.4	168	11.5
45–54	784	55	7.0	170	21.6	226	28.8	237	30.2	97	12.4
≥55	333	17	5.2	54	16.2	98	29.3	125	37.6	39	11.7
Native Hawaiian/other Pacific Islander
13–24	8	3	37.5	3	37.5	1	12.5	0	0.0	1	12.5
25–34	29	2	7.0	3	10.1	14	48.4	3	10.5	7	24.0
35–44	10	1	10.1	3	30.3	3	30.3	2	20.2	1	9.1
45–54	4	1	27.0	0	0.0	1	27.0	2	45.9	0	0.0
≥55	2	0	0.0	0	0.0	0	0.0	0	0.0	2	100
White
13–24	812	95	11.7	264	32.5	278	34.2	56	6.9	119	14.7
25–34	1,828	163	8.9	560	30.6	537	29.4	296	16.2	272	14.9
35–44	1,027	86	8.3	322	31.4	273	26.6	220	21.4	127	12.3
45–54	898	58	6.5	220	24.5	221	24.6	289	32.2	109	12.2
≥55	811	61	7.5	183	22.6	198	24.4	274	33.8	95	11.7
Multiracial
13–24	148	18	12.1	47	32.0	43	28.7	14	9.2	27	18.0
25–34	229	28	12.2	61	26.6	78	34.3	30	12.9	32	14.0
35–44	84	4	4.7	27	31.6	25	29.4	17	20.4	12	13.9
45–54	40	2	4.5	8	19.8	10	24.0	16	40.1	5	11.6
≥55	33	3	10.2	2	5.8	10	29.8	13	39.1	5	15.1
All
13–24	5,735	681	11.9	1,521	26.5	2,139	37.3	473	8.2	922	16.1
25–34	8,802	774	8.8	2,320	26.4	2,929	33.3	1,442	16.4	1,338	15.2
35–44	3,861	285	7.4	1,007	26.1	1,081	28.0	968	25.1	521	13.5
45–54	2,406	147	6.1	519	21.6	650	27.0	764	31.7	326	13.6
≥55	1,588	99	6.2	314	19.8	420	26.4	551	34.7	204	12.8
Total	22,392	1,985	8.9	5,681	25.4	7,219	32.2	4,196	18.7	3,310	14.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and includes transgender persons.

^aFirst positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^bIncludes persons with no CD4 information.
^cHispanic/Latino persons can be of any race.

Table 2a. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2019 among persons aged ≥13 years, by selected characteristics—44 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%	No.	%	No.	%
Gender
Male	26,827	21,873	81.5	4,954	18.5	23,767	88.6	3,060	11.4	18,382	68.5
Female	6,322	5,067	80.1	1,255	19.9	5,541	87.6	781	12.4	4,266	67.5
Transgender male-to-female^a	584	484	82.9	100	17.1	516	88.4	68	11.6	384	65.8
Transgender female-to-male^a	45	40	88.9	5	11.1	43	95.6	2	4.4	35	77.8
Additional gender identity^b	17	15	88.2	2	11.8	16	94.1	1	5.9	15	88.2
Age at diagnosis (yr)
13–24	7,093	5,602	79.0	1,491	21.0	6,191	87.3	902	12.7	4,835	68.2
25–34	12,105	9,775	80.8	2,330	19.2	10,640	87.9	1,465	12.1	8,223	67.9
35–44	6,560	5,405	82.4	1,155	17.6	5,851	89.2	709	10.8	4,517	68.9
45–54	4,523	3,767	83.3	756	16.7	4,050	89.5	473	10.5	3,121	69.0
≥55	3,514	2,930	83.4	584	16.6	3,151	89.7	363	10.3	2,386	67.9
Race/ethnicity
American Indian/Alaska Native	206	172	83.5	34	16.5	183	88.8	23	11.2	132	64.1
Asian	687	570	83.0	117	17.0	611	88.9	76	11.1	523	76.1
Black/African American	14,268	11,179	78.4	3,089	21.6	12,304	86.2	1,964	13.8	9,309	65.2
Hispanic/Latino^c	9,478	8,004	84.4	1,474	15.6	8,584	90.6	894	9.4	6,768	71.4
Native Hawaiian/other Pacific Islander	66	53	80.3	13	19.7	58	87.9	8	12.1	46	69.7
White	8,249	6,817	82.6	1,432	17.4	7,390	89.6	859	10.4	5,726	69.4
Multiracial	841	684	81.3	157	18.7	753	89.5	88	10.5	578	68.7
Transmission category^d
Male-to-male sexual contact	22,392	18,389	82.1	4,003	17.9	19,921	89.0	2,470	11.0	15,634	69.8
Injection drug use	2,175	1,640	75.4	535	24.6	1,826	84.0	348	16.0	1,187	54.6
Male	1,190	900	75.7	290	24.3	1,006	84.5	184	15.5	653	54.9
Female	985	740	75.1	245	24.9	821	83.3	164	16.7	534	54.2
Male-to-male sexual contact and injection drug use	1,347	1,080	80.2	267	19.8	1,202	89.2	145	10.8	872	64.7
Heterosexual contact^e	7,821	6,320	80.8	1,502	19.2	6,880	88.0	942	12.0	5,344	68.3
Male	2,459	1,969	80.1	490	19.9	2,134	86.8	325	13.2	1,594	64.8
Female	5,362	4,351	81.1	1,011	18.9	4,745	88.5	617	11.5	3,750	69.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	26,929	22,020	81.8	4,909	18.2	23,859	88.6	3,070	11.4	18,579	69.0
Metropolitan areas (pop. 50,000–499,999)	4,146	3,327	80.2	819	19.8	3,670	88.5	476	11.5	2,664	64.3
Nonmetropolitan areas (pop. <50,000)	2,133	1,709	80.1	424	19.9	1,881	88.2	252	11.8	1,439	67.5
Total^f	33,795	27,479	81.3	6,316	18.7	29,883	88.4	3,912	11.6	23,082	68.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cHispanic/Latino persons can be of any race.
^dData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2019, among persons aged ≥13 years, by area of residence—44 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
	Total	≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%	No.	%	No.	%
Alabama	638	505	79.2	133	20.8	556	87.1	82	12.9	431	67.6
Alaska	27	23	85.2	4	14.8	25	92.6	2	7.4	20	74.1
Arizona	761	630	82.8	131	17.2	685	90.0	76	10.0	533	70.0
Arkansas	287	229	79.8	58	20.2	258	89.9	29	10.1	176	61.3
California	4,354	3,601	82.7	753	17.3	3,865	88.8	489	11.2	2,940	67.5
Colorado	461	385	83.5	76	16.5	422	91.5	39	8.5	339	73.5
Connecticut	213	186	87.3	27	12.7	203	95.3	10	4.7	160	75.1
Delaware	93	71	76.3	22	23.7	78	83.9	15	16.1	65	69.9
District of Columbia	255	210	82.4	45	17.6	223	87.5	32	12.5	172	67.5
Florida	4,378	3,662	83.6	716	16.4	3,904	89.2	474	10.8	3,074	70.2
Georgia	2,439	1,961	80.4	478	19.6	2,115	86.7	324	13.3	1,636	67.1
Hawaii	65	55	84.6	10	15.4	59	90.8	6	9.2	50	76.9
Illinois	1,252	1,042	83.2	210	16.8	1,104	88.2	148	11.8	767	61.3
Indiana	486	307	63.2	179	36.8	370	76.1	116	23.9	268	55.1
Iowa	100	91	91.0	9	9.0	95	95.0	5	5.0	73	73.0
Louisiana	881	722	82.0	159	18.0	792	89.9	89	10.1	619	70.3
Maine	30	28	93.3	2	6.7	28	93.3	2	6.7	23	76.7
Maryland	918	798	86.9	120	13.1	833	90.7	85	9.3	649	70.7
Massachusetts	535	486	90.8	49	9.2	499	93.3	36	6.7	444	83.0
Michigan	674	565	83.8	109	16.2	617	91.5	57	8.5	519	77.0
Minnesota	274	250	91.2	24	8.8	258	94.2	16	5.8	201	73.4
Mississippi	477	339	71.1	138	28.9	403	84.5	74	15.5	283	59.3
Missouri	488	376	77.0	112	23.0	430	88.1	58	11.9	343	70.3
Montana	25	22	88.0	3	12.0	24	96.0	1	4.0	16	64.0
Nebraska	81	65	80.2	16	19.8	72	88.9	9	11.1	43	53.1
Nevada	512	425	83.0	87	17.0	455	88.9	57	11.1	310	60.5
New Hampshire	31	27	87.1	4	12.9	28	90.3	3	9.7	22	71.0
New Mexico	156	138	88.5	18	11.5	142	91.0	14	9.0	110	70.5
New York	2,330	2,027	87.0	303	13.0	2,149	92.2	181	7.8	1,823	78.2
North Carolina	1,365	1,077	78.9	288	21.1	1,229	90.0	136	10.0	975	71.4
North Dakota	40	36	90.0	4	10.0	39	97.5	1	2.5	34	85.0
Ohio	980	819	83.6	161	16.4	883	90.1	97	9.9	657	67.0
Oklahoma	320	222	69.4	98	30.6	253	79.1	67	20.9	162	50.6
Oregon	199	173	86.9	26	13.1	183	92.0	16	8.0	151	75.9
Rhode Island	72	65	90.3	7	9.7	69	95.8	3	4.2	59	81.9
South Carolina	680	596	87.6	84	12.4	643	94.6	37	5.4	518	76.2
South Dakota	33	26	78.8	7	21.2	31	93.9	2	6.1	18	54.5
Tennessee	773	534	69.1	239	30.9	640	82.8	133	17.2	488	63.1
Texas	4,302	3,210	74.6	1,092	25.4	3,596	83.6	706	16.4	2,539	59.0
Utah	135	106	78.5	29	21.5	124	91.9	11	8.1	106	78.5
Virginia	822	647	78.7	175	21.3	723	88.0	99	12.0	619	75.3
Washington	483	432	89.4	51	10.6	447	92.5	36	7.5	386	79.9
West Virginia	146	107	73.3	39	26.7	119	81.5	27	18.5	76	52.1
Wisconsin	211	190	90.0	21	10.0	199	94.3	12	5.7	178	84.4
Wyoming	13	13	100	0	0.0	13	100	0	0.0	7	53.8
Total	33,795	27,479	81.3	6,316	18.7	29,883	88.4	3,912	11.6	23,082	68.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

Table 2c. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2019, among persons aged ≥13 years, by race/ethnicity and selected characteristics—44 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
	Total	≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	157	130	82.8	27	17.2	138	87.9	19	12.1	107	68.2
Female	44	37	84.1	7	15.9	40	90.9	4	9.1	23	52.3
Transgender male-to-female^a	5	5	100	0	0.0	5	100	0	0.0	2	40.0
Transgender female-to-male^a	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
>13–24	46	40	87.0	6	13.0	45	97.8	1	2.2	32	69.6
25–34	63	54	85.7	9	14.3	56	88.9	7	11.1	46	73.0
35–44	57	48	84.2	9	15.8	50	87.7	7	12.3	31	54.4
45–54	27	21	77.8	6	22.2	22	81.5	5	18.5	17	63.0
≥55	13	9	69.2	4	30.8	10	76.9	3	23.1	6	46.2
Transmission category^c
Male-to-male sexual contact	123	106	85.6	18	14.4	112	90.4	12	9.6	88	71.5
Injection drug use
Male	15	12	75.3	4	24.7	13	82.5	3	17.5	6	40.9
Female	18	13	76.0	4	24.0	14	81.7	3	18.3	7	40.6
Male-to-male sexual contact and injection drug use	15	13	86.5	2	13.5	13	86.5	2	13.5	12	78.4
Heterosexual contact^d
Male	8	5	57.8	4	42.2	6	69.9	3	30.1	3	33.7
Female	27	24	89.4	3	10.6	26	97.0	1	3.0	16	60.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	107	88	82.2	19	17.8	95	88.8	12	11.2	69	64.5
Metropolitan areas (pop. 50,000–499,999)	32	28	87.5	4	12.5	29	90.6	3	9.4	23	71.9
Nonmetropolitan areas (pop. <50,000)	63	53	84.1	10	15.9	56	88.9	7	11.1	38	60.3
Total^e	206	172	83.5	34	16.5	183	88.8	23	11.2	132	64.1
Asian
Gender
Male	583	486	83.4	97	16.6	520	89.2	63	10.8	445	76.3
Female	92	73	79.3	19	20.7	80	87.0	12	13.0	69	75.0
Transgender male-to-female^a	11	10	90.9	1	9.1	10	90.9	1	9.1	8	72.7
Transgender female-to-male^a	1	1	100	0	0.0	1	100	0	0.0	1	100
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
>13–24	120	98	81.7	22	18.3	105	87.5	15	12.5	90	75.0
25–34	251	219	87.3	32	12.7	232	92.4	19	7.6	201	80.1
35–44	143	112	78.3	31	21.7	125	87.4	18	12.6	108	75.5
45–54	112	95	84.8	17	15.2	98	87.5	14	12.5	82	73.2
≥55	61	46	75.4	15	24.6	51	83.6	10	16.4	42	68.9
Transmission category^c
Male-to-male sexual contact	539	452	83.8	87	16.2	482	89.4	57	10.6	415	77.0
Injection drug use
Male	12	10	78.2	3	21.8	11	86.3	2	13.7	7	58.9
Female	6	4	67.7	2	32.3	4	69.4	2	30.6	4	69.4
Male-to-male sexual contact and injection drug use	13	10	77.0	3	23.0	11	86.5	2	13.5	10	81.0
Heterosexual contact^d
Male	27	22	83.8	4	16.2	24	90.6	3	9.4	19	72.6
Female	86	69	80.4	17	19.6	76	88.4	10	11.6	65	75.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	615	509	82.8	106	17.2	546	88.8	69	11.2	471	76.6
Metropolitan areas (pop. 50,000–499,999)	51	43	84.3	8	15.7	46	90.2	5	9.8	37	72.5
Nonmetropolitan areas (pop. <50,000)	15	14	93.3	1	6.7	15	100	0	0.0	14	93.3
Total^e	687	570	83.0	117	17.0	611	88.9	76	11.1	523	76.1
Black/African American
Gender
Male	10,478	8,145	77.7	2,333	22.3	8,991	85.8	1,487	14.2	6,724	64.2
Female	3,498	2,800	80.0	698	20.0	3,063	87.6	435	12.4	2,399	68.6
Transgender male-to-female^a	269	213	79.2	56	20.8	228	84.8	41	15.2	168	62.5
Transgender female-to-male^a	19	18	94.7	1	5.3	19	100	0	0.0	15	78.9
Additional gender identity^b	4	3	75.0	1	25.0	3	75.0	1	25.0	3	75.0
Age at diagnosis (yr)
>13–24	3,650	2,813	77.1	837	22.9	3,136	85.9	514	14.1	2,399	65.7
25–34	5,025	3,869	77.0	1,156	23.0	4,276	85.1	749	14.9	3,218	64.0
35–44	2,393	1,918	80.2	475	19.8	2,087	87.2	306	12.8	1,585	66.2
45–54	1,676	1,350	80.5	326	19.5	1,472	87.8	204	12.2	1,107	66.1
≥55	1,524	1,229	80.6	295	19.4	1,333	87.5	191	12.5	1,000	65.6
Transmission category^c
Male-to-male sexual contact	8,571	6,701	78.2	1,870	21.8	7,398	86.3	1,173	13.7	5,574	65.0
Injection drug use
Male	360	265	73.7	95	26.3	292	81.2	68	18.8	201	55.9
Female	277	211	76.1	66	23.9	232	83.7	45	16.3	164	59.3
Male-to-male sexual contact and injection drug use	274	208	76.0	66	24.0	232	85.0	41	15.0	155	56.7
Heterosexual contact^d
Male	1,528	1,172	76.7	357	23.3	1,284	84.0	244	16.0	953	62.4
Female	3,226	2,595	80.4	631	19.6	2,838	88.0	388	12.0	2,237	69.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	11,265	8,875	78.8	2,390	21.2	9,720	86.3	1,545	13.7	7,367	65.4
Metropolitan areas (pop. 50,000–499,999)	1,777	1,398	78.7	379	21.3	1,546	87.0	231	13.0	1,117	62.9
Nonmetropolitan areas (pop. <50,000)	867	654	75.4	213	24.6	751	86.6	116	13.4	584	67.4
Total^e	14,268	11,179	78.4	3,089	21.6	12,304	86.2	1,964	13.8	9,309	65.2
Hispanic/Latino^f
Gender
Male	8,116	6,861	84.5	1,255	15.5	7,357	90.6	759	9.4	5,805	71.5
Female	1,136	949	83.5	187	16.5	1,018	89.6	118	10.4	803	70.7
Transgender male-to-female^a	211	180	85.3	31	14.7	195	92.4	16	7.6	149	70.6
Transgender female-to-male^a	11	10	90.9	1	9.1	10	90.9	1	9.1	8	72.7
Additional gender identity^b	4	4	100	0	0.0	4	100	0	0.0	3	75.0
Age at diagnosis (yr)
>13–24	1,974	1,624	82.3	350	17.7	1,768	89.6	206	10.4	1,407	71.3
25–34	3,632	3,087	85.0	545	15.0	3,299	90.8	333	9.2	2,613	71.9
35–44	2,051	1,743	85.0	308	15.0	1,864	90.9	187	9.1	1,476	72.0
45–54	1,179	1,001	84.9	178	15.1	1,065	90.3	114	9.7	830	70.4
≥55	642	549	85.5	93	14.5	588	91.6	54	8.4	442	68.8
Transmission category^c
Male-to-male sexual contact	7,196	6,104	84.8	1,092	15.2	6,532	90.8	663	9.2	5,241	72.8
Injection drug use
Male	263	207	78.8	56	21.2	230	87.4	33	12.6	143	54.4
Female	156	126	80.9	30	19.1	134	86.1	22	13.9	88	56.2
Male-to-male sexual contact and injection drug use	373	301	80.8	72	19.2	335	89.9	38	10.1	234	62.8
Heterosexual contact^d
Male	489	424	86.6	66	13.4	449	91.7	41	8.3	330	67.4
Female	988	831	84.1	157	15.9	891	90.2	97	9.8	721	72.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,263	7,004	84.8	1,259	15.2	7,494	90.7	769	9.3	5,981	72.4
Metropolitan areas (pop. 50,000–499,999)	800	652	81.5	148	18.5	725	90.6	75	9.4	516	64.5
Nonmetropolitan areas (pop. <50,000)	327	284	86.9	43	13.1	297	90.8	30	9.2	211	64.5
Total^e	9,478	8,004	84.4	1,474	15.6	8,584	90.6	894	9.4	6,768	71.4
Native Hawaiian/other Pacific Islander
Gender
Male	52	43	82.7	9	17.3	46	88.5	6	11.5	37	71.2
Female	9	7	77.8	2	22.2	8	88.9	1	11.1	6	66.7
Transgender male-to-female^a	5	3	60.0	2	40.0	4	80.0	1	20.0	3	60.0
Transgender female-to-male^a	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Age at diagnosis (yr)
>13–24	10	8	80.0	2	20.0	10	100	0	0.0	8	80.0
25–34	35	29	82.9	6	17.1	31	88.6	4	11.4	25	71.4
35–44	14	11	78.6	3	21.4	12	85.7	2	14.3	10	71.4
45–54	5	5	100	0	0.0	5	100	0	0.0	3	60.0
≥55	2	0	0.0	2	100	0	0.0	2	100	0	0.0
Transmission category^c
Male-to-male sexual contact	52	43	83.3	9	16.7	46	89.1	6	10.9	37	71.8
Injection drug use
Male	1	0	8.3	1	91.7	0	8.3	1	91.7	0	8.3
Female	0	0	100	0	0.0	0	100	0	0.0	0	100
Male-to-male sexual contact and injection drug use	2	1	52.4	1	47.6	2	100	0	0.0	1	52.4
Heterosexual contact^d
Male	2	1	93.3	0	6.7	1	93.3	0	6.7	1	93.3
Female	9	7	77.0	2	23.0	8	88.5	1	11.5	6	65.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	51	40	78.4	11	21.6	45	88.2	6	11.8	35	68.6
Metropolitan areas (pop. 50,000–499,999)	11	9	81.8	2	18.2	9	81.8	2	18.2	7	63.6
Nonmetropolitan areas (pop. <50,000)	4	4	100	0	0.0	4	100	0	0.0	4	100
Total^e	66	53	80.3	13	19.7	58	87.9	8	12.1	46	69.7
White
Gender
Male	6,805	5,689	83.6	1,116	16.4	6,145	90.3	660	9.7	4,826	70.9
Female	1,357	1,052	77.5	305	22.5	1,165	85.9	192	14.1	839	61.8
Transgender male-to-female^a	71	64	90.1	7	9.9	65	91.5	6	8.5	47	66.2
Transgender female-to-male^a	11	8	72.7	3	27.3	10	90.9	1	9.1	9	81.8
Additional gender identity^b	5	4	80.0	1	20.0	5	100	0	0.0	5	100
Age at diagnosis (yr)
>13–24	1,107	871	78.7	236	21.3	968	87.4	139	12.6	770	69.6
25–34	2,759	2,246	81.4	513	18.6	2,444	88.6	315	11.4	1,896	68.7
35–44	1,749	1,448	82.8	301	17.2	1,572	89.9	177	10.1	1,193	68.2
45–54	1,431	1,217	85.0	214	15.0	1,301	90.9	130	9.1	1,013	70.8
≥55	1,203	1,035	86.0	168	14.0	1,105	91.9	98	8.1	854	71.0
Transmission category^c
Male-to-male sexual contact	5,376	4,544	84.5	832	15.5	4,874	90.7	501	9.3	3,905	72.6
Injection drug use
Male	513	386	75.2	127	24.8	436	85.0	77	15.0	279	54.4
Female	490	356	72.7	134	27.3	405	82.6	85	17.4	250	51.1
Male-to-male sexual contact and injection drug use	622	513	82.4	109	17.6	568	91.2	55	8.8	432	69.4
Heterosexual contact^d
Male	363	309	85.1	54	14.9	330	91.1	32	8.9	257	70.9
Female	875	701	80.1	174	19.9	767	87.7	107	12.3	596	68.1
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	5,959	4,961	83.3	998	16.7	5,364	90.0	595	10.0	4,190	70.3
Metropolitan areas (pop. 50,000–499,999)	1,365	1,108	81.2	257	18.8	1,216	89.1	149	10.9	895	65.6
Nonmetropolitan areas (pop. <50,000)	805	656	81.5	149	18.5	709	88.1	96	11.9	554	68.8
Total^e	8,249	6,817	82.6	1,432	17.4	7,390	89.6	859	10.4	5,726	69.4
Multiracial
Gender
Male	636	519	81.6	117	18.4	570	89.6	66	10.4	438	68.9
Female	186	149	80.1	37	19.9	167	89.8	19	10.2	127	68.3
Transgender male-to-female^a	12	9	75.0	3	25.0	9	75.0	3	25.0	7	58.3
Transgender female-to-male^a	3	3	100	0	0.0	3	100	0	0.0	2	66.7
Additional gender identity^b	4	4	100	0	0.0	4	100	0	0.0	4	100
Age at diagnosis (yr)
>13–24	186	148	79.6	38	20.4	159	85.5	27	14.5	129	69.4
25–34	340	271	79.7	69	20.3	302	88.8	38	11.2	224	65.9
35–44	153	125	81.7	28	18.3	141	92.2	12	7.8	114	74.5
45–54	93	78	83.9	15	16.1	87	93.5	6	6.5	69	74.2
≥55	69	62	89.9	7	10.1	64	92.8	5	7.2	42	60.9
Transmission category^c
Male-to-male sexual contact	534	439	82.2	95	17.8	477	89.3	57	10.7	374	70.0
Injection drug use
Male	25	20	81.8	5	18.2	23	94.7	1	5.3	15	61.9
Female	38	29	76.0	9	24.0	31	82.1	7	17.9	20	52.5
Male-to-male sexual contact and injection drug use	49	35	70.9	14	29.1	41	83.7	8	16.3	28	56.6
Heterosexual contact^d
Male	42	36	85.6	6	14.4	40	94.1	3	5.9	30	71.5
Female	152	124	81.6	28	18.4	140	91.9	12	8.1	110	72.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	669	543	81.2	126	18.8	595	88.9	74	11.1	466	69.7
Metropolitan areas (pop. 50,000–499,999)	110	89	80.9	21	19.1	99	90.0	11	10.0	69	62.7
Nonmetropolitan areas (pop. <50,000)	52	44	84.6	8	15.4	49	94.2	3	5.8	34	65.4
Total^e	841	684	81.3	157	18.7	753	89.5	88	10.5	578	68.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^dHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^eIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
^fHispanic/Latino persons can be of any race.

Table 2d. Linkage to HIV medical care and viral suppression within 6 months of HIV diagnosis during 2019, among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—44 states and the District of Columbia
		Linkage to Care								Viral Suppression
		≤1 month				≤3 months
	Total	≥1 CD4 or VL tests		No CD4 or VL test		≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	33	28	85.7	5	14.3	32	97.9	1	2.1	21	64.4
25–34	45	39	87.2	6	12.8	40	89.5	5	10.5	33	74.5
35–44	25	23	89.8	3	10.2	23	89.8	3	10.2	20	78.0
45–54	14	11	79.7	3	20.3	12	86.2	2	13.8	10	72.5
≥55	7	5	70.8	2	29.2	5	70.8	2	29.2	4	58.5
Asian
13–24	107	87	81.6	20	18.4	93	87.2	14	12.8	81	75.5
25–34	210	184	87.5	26	12.5	194	92.1	17	7.9	168	79.9
35–44	111	87	77.9	25	22.1	97	87.6	14	12.4	85	76.1
45–54	80	71	88.8	9	11.2	72	90.0	8	10.0	61	75.8
≥55	30	23	75.3	8	24.7	25	83.2	5	16.8	21	68.4
Black/African American
13–24	2,948	2,283	77.4	665	22.6	2,551	86.5	398	13.5	1,957	66.4
25–34	3,523	2,731	77.5	792	22.5	3,017	85.7	505	14.3	2,249	63.8
35–44	1,141	915	80.2	226	19.8	994	87.0	148	13.0	749	65.6
45–54	585	468	79.9	118	20.1	511	87.3	75	12.7	382	65.2
≥55	373	304	81.4	69	18.6	325	87.2	48	12.8	238	63.7
Hispanic/Latino^a
13–24	1,678	1,381	82.3	297	17.7	1,509	89.9	169	10.1	1,203	71.7
25–34	2,939	2,518	85.7	422	14.3	2,680	91.2	260	8.8	2,149	73.1
35–44	1,461	1,242	85.0	220	15.0	1,322	90.5	139	9.5	1,085	74.3
45–54	784	679	86.6	105	13.4	716	91.3	68	8.7	576	73.4
≥55	333	284	85.4	49	14.6	306	92.0	27	8.0	228	68.6
Native Hawaiian/other Pacific Islander
13–24	8	7	87.5	1	12.5	8	100	0	0.0	7	87.5
25–34	29	24	82.6	5	17.4	26	89.5	3	10.5	20	68.6
35–44	10	9	90.9	1	9.1	9	90.9	1	9.1	9	90.9
45–54	4	4	100	0	0.0	4	100	0	0.0	2	45.9
≥55	2	0	0.0	2	100	0	0.0	2	100	0	0.0
White
13–24	812	648	79.7	165	20.3	718	88.4	94	11.6	587	72.3
25–34	1,828	1,535	84.0	292	16.0	1,636	89.5	192	10.5	1,322	72.4
35–44	1,027	866	84.3	161	15.7	938	91.3	89	8.7	748	72.8
45–54	898	783	87.2	115	12.8	833	92.8	65	7.2	663	73.9
≥55	811	712	87.8	99	12.2	749	92.4	61	7.6	584	72.1
Multiracial
13–24	148	118	79.5	30	20.5	129	86.7	20	13.3	103	69.4
25–34	229	190	82.9	39	17.1	205	89.7	24	10.3	154	67.3
35–44	84	69	81.5	16	18.5	77	90.9	8	9.1	63	75.0
45–54	40	34	84.7	6	15.3	37	91.6	3	8.4	33	80.4
≥55	33	29	88.6	4	11.4	30	91.1	3	8.9	21	65.8
All
13–24	5,735	4,552	79.4	1,183	20.6	5,040	87.9	695	12.1	3,958	69.0
25–34	8,802	7,220	82.0	1,582	18.0	7,797	88.6	1,005	11.4	6,096	69.3
35–44	3,861	3,210	83.1	651	16.9	3,460	89.6	401	10.4	2,759	71.5
45–54	2,406	2,050	85.2	356	14.8	2,185	90.8	221	9.2	1,726	71.7
≥55	1,588	1,356	85.4	232	14.6	1,440	90.7	148	9.3	1,096	69.0
Total	22,392	18,389	82.1	4,003	17.9	19,921	89.0	2,470	11.0	15,634	69.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month or ≤3 months after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2019. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aHispanic/Latino persons can be of any race.

Table 3a. Receipt of HIV medical care among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by selected characteristics—44 states and the District of Columbia
	Persons alive at year-end 2019	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a
	Total No.	No.	%	No.	%
Gender
Male	702,412	533,401	75.9	404,656	57.6
Female	212,405	160,947	75.8	122,955	57.9
Transgender male-to-female^b	9,699	8,190	84.4	6,452	66.5
Transgender female-to-male^b	391	334	85.4	253	64.7
Additional gender identity^c	170	151	88.8	125	73.5
Age at year-end 2018 (yr)
13–24	29,533	23,615	80.0	17,346	58.7
25–34	147,061	114,125	77.6	81,883	55.7
35–44	175,204	132,214	75.5	97,169	55.5
45–54	254,886	194,838	76.4	148,607	58.3
≥55	318,393	238,231	74.8	189,436	59.5
Race/ethnicity
American Indian/Alaska Native	2,924	2,236	76.5	1,664	56.9
Asian^d	13,903	10,495	75.5	8,178	58.8
Black/African American	371,711	273,801	73.7	206,196	55.5
Hispanic/Latino^e	220,914	163,537	74.0	129,539	58.6
Native Hawaiian/other Pacific Islander	815	602	73.9	431	52.9
White	270,980	215,050	79.4	159,945	59.0
Multiracial	43,145	37,243	86.3	28,440	65.9
Transmission category^f
Male-to-male sexual contact	528,606	410,672	77.7	309,723	58.6
Injection drug use	98,290	66,875	68.0	51,968	52.9
Male	56,813	36,326	63.9	28,477	50.1
Female	41,478	30,549	73.7	23,491	56.6
Male-to-male sexual contact and injection drug use	51,307	40,865	79.6	31,520	61.4
Heterosexual contact^g	233,549	174,765	74.8	133,758	57.3
Male	68,761	48,995	71.3	37,906	55.1
Female	164,787	125,770	76.3	95,852	58.2
Other^h
Male	6,771	4,864	71.8	3,590	53.0
Female	6,554	4,981	76.0	3,882	59.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	754,205	573,250	76.0	436,448	57.9
Metropolitan areas (pop. 50,000–499,999)	93,099	72,080	77.4	54,368	58.4
Nonmetropolitan areas (pop. <50,000)	52,469	39,948	76.1	30,331	57.8
Totalⁱ	925,077	703,023	76.0	534,441	57.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aPerformed ≥3 months apart during 2019.
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified.
ⁱIncludes 685 persons of unknown race/ethnicity.

Table 3b. Receipt of HIV medical care among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence—44 states and the District of Columbia
	Persons alive at year-end 2019	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a
	Total No.	No.	%	No.	%
Alabama	13,245	10,325	78.0	8,067	60.9
Alaska	700	616	88.0	424	60.6
Arizona	16,537	12,323	74.5	9,818	59.4
Arkansas	5,668	3,721	65.6	2,713	47.9
California	128,592	98,773	76.8	75,158	58.4
Colorado	12,556	8,427	67.1	5,724	45.6
Connecticut	10,380	8,361	80.5	6,194	59.7
Delaware	3,286	2,749	83.7	1,959	59.6
District of Columbia	13,777	9,463	68.7	7,026	51.0
Florida	109,195	84,213	77.1	69,134	63.3
Georgia	54,031	39,619	73.3	31,125	57.6
Hawaii	2,324	1,925	82.8	1,411	60.7
Illinois	34,564	24,366	70.5	16,504	47.7
Indiana	11,145	8,070	72.4	5,480	49.2
Iowa	2,785	2,452	88.0	1,845	66.2
Louisiana	20,425	16,185	79.2	12,736	62.4
Maine	1,613	1,368	84.8	1,066	66.1
Maryland	32,466	23,932	73.7	17,880	55.1
Massachusetts^b	20,514	16,162	78.8	11,956	58.3
Michigan	15,903	13,332	83.8	9,591	60.3
Minnesota	8,532	6,708	78.6	4,316	50.6
Mississippi^b	9,356	6,830	73.0	5,076	54.3
Missouri	12,320	9,630	78.2	7,230	58.7
Montana	638	569	89.2	413	64.7
Nebraska	2,151	1,652	76.8	1,054	49.0
Nevada^b	10,228	7,047	68.9	3,499	34.2
New Hampshire	1,273	1,042	81.9	765	60.1
New Mexico	3,582	2,664	74.4	1,806	50.4
New York	124,135	92,597	74.6	77,565	62.5
North Carolina	31,640	24,495	77.4	17,447	55.1
North Dakota^b	456	371	81.4	250	54.8
Ohio	22,204	16,766	75.5	11,371	51.2
Oklahoma	6,033	4,244	70.3	3,215	53.3
Oregon	7,080	6,313	89.2	4,255	60.1
Rhode Island	2,584	2,206	85.4	1,528	59.1
South Carolina	16,917	13,701	81.0	11,256	66.5
South Dakota	618	506	81.9	336	54.4
Tennessee	16,957	13,929	82.1	10,647	62.8
Texas	90,852	68,574	75.5	49,885	54.9
Utah	2,947	2,287	77.6	1,586	53.8
Virginia	22,870	15,972	69.8	11,788	51.5
Washington	13,539	11,688	86.3	8,293	61.3
West Virginia	1,847	1,373	74.3	963	52.1
Wisconsin	6,279	5,204	82.9	3,871	61.6
Wyoming	333	273	82.0	215	64.6
Total	925,077	703,023	76.0	534,441	57.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address).
Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020.
Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aPerformed ≥3 months apart during 2019.
^bData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 3c. Receipt of HIV medical care and viral suppression among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by race/ethnicity and selected characteristics—44 states and the District of Columbia
	Persons alive at year-end 2019	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	2,141	1,638	76.5	1,217	56.8	1,374	64.2
Female	735	559	76.1	415	56.5	436	59.3
Transgender male-to-female^c	43	35	81.4	30	69.8	23	53.5
Transgender female-to-female^c	4	3	75.0	2	50.0	2	50.0
Additional gender identity^d	1	1	100	0	0.0	1	100
Age at year-end 2018 (yr)
13–24	106	81	76.4	61	57.5	61	57.5
25–34	576	453	78.6	313	54.3	350	60.8
35–44	644	501	77.8	365	56.7	403	62.6
45–54	821	612	74.5	464	56.5	512	62.4
≥55	777	589	75.8	461	59.3	510	65.6
Transmission category^e
Male-to-male sexual contact	1,538	1,186	77.1	888	57.8	996	64.7
Injection drug use
Male	216	154	71.3	107	49.4	121	56.2
Female	247	184	74.5	138	55.8	135	54.4
Male-to-male sexual contact and injection drug use	271	208	76.7	168	62.0	173	63.7
Heterosexual contact^f
Male	143	112	78.2	74	52.0	98	68.4
Female	473	368	77.9	272	57.5	295	62.4
Other^g
Male	17	14	81.8	10	55.9	11	62.9
Female	19	9	48.9	7	37.9	8	43.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	1,546	1,121	72.5	830	53.7	917	59.3
Metropolitan areas (pop. 50,000–499,999)	518	434	83.8	336	64.9	376	72.6
Nonmetropolitan areas (pop. <50,000)	800	638	79.8	472	59.0	515	64.4
Total	2,924	2,236	76.5	1,664	56.9	1,836	62.8
Asian^h
Gender
Male	11,379	8,652	76.0	6,750	59.3	8,046	70.7
Female	2,357	1,701	72.2	1,320	56.0	1,555	66.0
Transgender male-to-female^c	156	131	84.0	99	63.5	119	76.3
Transgender female-to-female^c	6	6	100	4	66.7	6	100
Additional gender identity^d	5	5	100	5	100	5	100
Age at year-end 2018 (yr)
13–24	508	434	85.4	345	67.9	406	79.9
25–34	2,649	2,036	76.9	1,574	59.4	1,901	71.8
35–44	3,544	2,658	75.0	2,042	57.6	2,464	69.5
45–54	4,043	3,102	76.7	2,376	58.8	2,864	70.8
≥55	3,159	2,265	71.7	1,841	58.3	2,096	66.4
Transmission category^e
Male-to-male sexual contact	9,779	7,510	76.8	5,822	59.5	7,015	71.7
Injection drug use
Male	386	258	66.8	210	54.3	232	60.2
Female	165	102	61.7	80	48.5	89	54.0
Male-to-male sexual contact and injection drug use	365	287	78.6	219	60.1	246	67.5
Heterosexual contact^f
Male	894	650	72.7	536	60.0	603	67.5
Female	2,099	1,531	72.9	1,177	56.1	1,401	66.8
Other^g
Male	115	82	71.5	66	56.9	72	62.8
Female	100	75	75.1	68	67.9	72	71.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	12,551	9,530	75.9	7,451	59.4	8,849	70.5
Metropolitan areas (pop. 50,000–499,999)	852	622	73.0	478	56.1	573	67.3
Nonmetropolitan areas (pop. <50,000)	228	163	71.5	122	53.5	148	64.9
Total	13,903	10,495	75.5	8,178	58.8	9,731	70.0
Black/African American
Gender
Male	242,900	177,024	72.9	132,522	54.6	145,500	59.9
Female	124,207	92,918	74.8	70,683	56.9	77,448	62.4
Transgender male-to-female^c	4,364	3,662	83.9	2,836	65.0	2,801	64.2
Transgender female-to-female^c	175	143	81.7	109	62.3	107	61.1
Additional gender identity^d	65	54	83.1	46	70.8	43	66.2
Age at year-end 2018 (yr)
13–24	16,242	12,629	77.8	9,238	56.9	9,525	58.6
25–34	69,916	52,575	75.2	37,125	53.1	40,175	57.5
35–44	71,140	52,613	74.0	38,263	53.8	42,367	59.6
45–54	94,893	70,660	74.5	53,901	56.8	59,492	62.7
≥55	119,520	85,324	71.4	67,669	56.6	74,340	62.2
Transmission category^e
Male-to-male sexual contact	161,072	121,057	75.2	89,196	55.4	99,297	61.6
Injection drug use
Male	26,496	16,635	62.8	12,982	49.0	13,812	52.1
Female	19,674	14,176	72.1	10,976	55.8	11,793	59.9
Male-to-male sexual contact and injection drug use	13,725	10,439	76.1	8,169	59.5	8,321	60.6
Heterosexual contact^f
Male	42,937	30,484	71.0	23,466	54.7	25,394	59.1
Female	101,072	76,157	75.3	57,688	57.1	63,813	63.1
Other^g
Male	3,092	2,119	68.5	1,587	51.3	1,515	49.0
Female	3,642	2,734	75.1	2,133	58.6	1,954	53.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	303,373	223,260	73.6	167,415	55.2	184,200	60.7
Metropolitan areas (pop. 50,000–499,999)	36,537	27,443	75.1	20,973	57.4	22,570	61.8
Nonmetropolitan areas (pop. <50,000)	20,546	15,369	74.8	12,038	58.6	12,610	61.4
Total	371,711	273,801	73.7	206,196	55.5	225,899	60.8
Hispanic/Latinoⁱ
Gender
Male	176,370	128,701	73.0	101,493	57.5	112,731	63.9
Female	40,990	31,857	77.7	25,629	62.5	27,541	67.2
Transgender male-to-female^c	3,419	2,859	83.6	2,322	67.9	2,339	68.4
Transgender female-to-female^c	85	74	87.1	58	68.2	62	72.9
Additional gender identity^d	50	46	92.0	37	74.0	36	72.0
Age at year-end 2018 (yr)
13–24	7,406	6,135	82.8	4,563	61.6	5,010	67.6
25–34	39,518	31,361	79.4	23,429	59.3	26,145	66.2
35–44	50,675	37,041	73.1	28,608	56.5	31,733	62.6
45–54	62,961	45,919	72.9	36,980	58.7	40,606	64.5
≥55	60,354	43,081	71.4	35,959	59.6	39,215	65.0
Transmission category^e
Male-to-male sexual contact	135,301	101,756	75.2	79,807	59.0	90,078	66.6
Injection drug use
Male	16,340	9,628	58.9	7,937	48.6	8,143	49.8
Female	8,427	6,401	76.0	5,167	61.3	5,356	63.6
Male-to-male sexual contact and injection drug use	12,501	9,663	77.3	7,646	61.2	7,807	62.5
Heterosexual contact^f
Male	14,214	9,475	66.7	7,627	53.7	8,251	58.0
Female	31,211	24,388	78.1	19,601	62.8	21,386	68.5
Other^g
Male	1,477	1,079	73.0	829	56.1	823	55.7
Female	1,443	1,148	79.5	925	64.1	865	59.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	193,348	144,350	74.7	114,748	59.3	126,230	65.3
Metropolitan areas (pop. 50,000–499,999)	14,778	10,570	71.5	8,013	54.2	9,169	62.0
Nonmetropolitan areas (pop. <50,000)	7,358	4,511	61.3	3,472	47.2	3,749	51.0
Total	220,914	163,537	74.0	129,539	58.6	142,709	64.6
Native Hawaiian/other Pacific Islander
Gender
Male	661	490	74.1	352	53.3	432	65.4
Female	125	88	70.4	62	49.6	76	60.8
Transgender male-to-female^c	29	24	82.8	17	58.6	21	72.4
Transgender female-to-female^c	0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0
Age at year-end 2018 (yr)
13–24	31	22	71.0	17	54.8	20	64.5
25–34	172	129	75.0	85	49.4	106	61.6
35–44	205	143	69.8	98	47.8	121	59.0
45–54	208	156	75.0	112	53.8	138	66.3
≥55	199	152	76.4	119	59.8	144	72.4
Transmission category^e
Male-to-male sexual contact	590	435	73.8	308	52.2	391	66.2
Injection drug use
Male	22	16	73.2	12	54.0	11	50.4
Female	20	13	64.0	11	52.2	11	53.7
Male-to-male sexual contact and injection drug use	41	34	82.6	28	67.4	26	63.0
Heterosexual contact^f
Male	32	24	75.3	17	53.1	21	66.0
Female	104	75	72.2	51	49.5	65	62.6
Other^g
Male	4	4	95.3	4	95.3	4	95.3
Female	1	0	25.0	0	16.7	0	25.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	658	489	74.3	353	53.6	424	64.4
Metropolitan areas (pop. 50,000–499,999)	87	63	72.4	46	52.9	63	72.4
Nonmetropolitan areas (pop. <50,000)	46	35	76.1	22	47.8	28	60.9
Total	815	602	73.9	431	52.9	529	64.9
White
Gender
Male	235,825	188,666	80.0	140,849	59.7	170,502	72.3
Female	34,076	25,442	74.7	18,383	53.9	22,112	64.9
Transgender male-to-female^c	959	836	87.2	631	65.8	702	73.2
Transgender female-to-female^c	91	80	87.9	60	65.9	66	72.5
Additional gender identity^d	29	26	89.7	22	75.9	20	69.0
Age at year-end 2018 (yr)
13–24	3,902	3,203	82.1	2,301	59.0	2,798	71.7
25–34	26,778	21,421	80.0	14,949	55.8	18,447	68.9
35–44	40,306	31,957	79.3	22,444	55.7	27,780	68.9
45–54	79,701	63,812	80.1	46,660	58.5	57,174	71.7
≥55	120,293	94,657	78.7	73,591	61.2	87,203	72.5
Transmission category^e
Male-to-male sexual contact	195,335	157,446	80.6	117,648	60.2	143,640	73.5
Injection drug use
Male	11,180	7,810	69.9	5,780	51.7	6,646	59.4
Female	10,488	7,561	72.1	5,450	52.0	6,318	60.2
Male-to-male sexual contact and injection drug use	20,566	16,834	81.9	12,595	61.2	14,335	69.7
Heterosexual contact^f
Male	8,076	6,199	76.8	4,623	57.2	5,494	68.0
Female	22,720	17,274	76.0	12,494	55.0	15,252	67.1
Other^g
Male	1,649	1,236	74.9	853	51.7	1,107	67.1
Female	966	691	71.6	502	52.0	610	63.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	206,824	163,820	79.2	122,152	59.1	147,781	71.5
Metropolitan areas (pop. 50,000–499,999)	36,148	29,376	81.3	21,859	60.5	26,284	72.7
Nonmetropolitan areas (pop. <50,000)	20,998	17,080	81.3	12,532	59.7	15,149	72.1
Total	270,980	215,050	79.4	159,945	59.0	193,402	71.4
Multiracial
Gender
Male	32,635	28,180	86.3	21,432	65.7	24,119	73.9
Female	9,731	8,373	86.0	6,456	66.3	6,936	71.3
Transgender male-to-female^c	729	643	88.2	517	70.9	498	68.3
Transgender female-to-female^c	30	28	93.3	20	66.7	24	80.0
Additional gender identity^d	20	19	95.0	15	75.0	15	75.0
Age at year-end 2018 (yr)
13–24	1,332	1,110	83.3	821	61.6	860	64.6
25–34	7,438	6,147	82.6	4,406	59.2	4,861	65.4
35–44	8,663	7,298	84.2	5,346	61.7	6,020	69.5
45–54	12,068	10,564	87.5	8,102	67.1	9,027	74.8
≥55	13,644	12,124	88.9	9,765	71.6	10,824	79.3
Transmission category^e
Male-to-male sexual contact	24,643	21,244	86.2	16,023	65.0	18,369	74.5
Injection drug use
Male	2,108	1,820	86.3	1,445	68.5	1,518	72.0
Female	2,398	2,110	88.0	1,668	69.6	1,714	71.5
Male-to-male sexual contact and injection drug use	3,791	3,399	89.7	2,694	71.1	2,749	72.5
Heterosexual contact^f
Male	2,437	2,049	84.1	1,560	64.0	1,744	71.5
Female	6,997	5,971	85.3	4,563	65.2	5,016	71.7
Other^g
Male	403	328	81.4	240	59.6	252	62.5
Female	368	322	87.4	247	67.0	231	62.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	35,386	30,621	86.5	23,451	66.3	25,998	73.5
Metropolitan areas (pop. 50,000–499,999)	4,143	3,572	86.2	2,663	64.3	3,016	72.8
Nonmetropolitan areas (pop. <50,000)	2,453	2,152	87.7	1,673	68.2	1,824	74.4
Total	43,145	37,243	86.3	28,440	65.9	31,592	73.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aPerformed ≥3 months apart during 2019.
^bVL test results are from the most recent test during 2019.
^c“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^dAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^eData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified.
^hIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
ⁱHispanic/Latino persons can be of any race.

Table 3d. Receipt of HIV medical care and viral suppression during 2019 among males aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age group—44 states and the District of Columbia
	Males alive at year-end 2019	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	76	61	80.5	45	59.8	48	63.5
25–34	390	318	81.6	221	56.7	259	66.4
35–44	344	268	77.7	195	56.6	223	64.8
45–54	402	300	74.6	239	59.4	258	64.2
≥55	326	240	73.6	188	57.7	208	63.7
Subtotal	1,538	1,187	77.2	888	57.7	996	64.8
Asian^c
13–24	369	315	85.4	243	65.9	301	81.4
25–34	2,173	1,676	77.1	1,296	59.6	1,579	72.7
35–44	2,424	1,840	75.9	1,389	57.3	1,711	70.6
45–54	2,793	2,180	78.0	1,678	60.1	2,025	72.5
≥55	2,020	1,499	74.2	1,217	60.2	1,400	69.3
Subtotal	9,779	7,510	76.8	5,823	59.5	7,016	71.7
Black/African American
13–24	10,371	8,190	79.0	5,880	56.7	6,359	61.3
25–34	48,433	37,165	76.7	26,165	54.0	28,867	59.6
35–44	32,830	24,960	76.0	18,092	55.1	20,279	61.8
45–54	35,334	26,368	74.6	20,016	56.6	22,482	63.6
≥55	34,104	24,374	71.5	19,042	55.8	21,309	62.5
Subtotal	161,072	121,057	75.2	89,195	55.4	99,296	61.6
Hispanic/Latino^d
13–24	5,344	4,482	83.9	3,296	61.7	3,753	70.2
25–34	30,327	24,314	80.2	18,102	59.7	20,655	68.1
35–44	33,359	24,599	73.7	18,991	56.9	21,548	64.6
45–54	37,689	27,592	73.2	22,165	58.8	24,960	66.2
≥55	28,582	20,769	72.7	17,253	60.4	19,161	67.0
Subtotal	135,301	101,756	75.2	79,807	59.0	90,077	66.6
Native Hawaiian/other Pacific Islander
13–24	22	15	68.0	11	50.2	13	58.9
25–34	137	102	74.7	69	50.7	87	63.7
35–44	154	108	70.1	73	47.5	96	62.4
45–54	150	110	73.6	77	51.6	99	66.2
≥55	127	100	78.5	77	60.6	95	74.6
Subtotal	590	435	73.7	307	52.0	390	66.1
White
13–24	2,555	2,120	83.0	1,525	59.7	1,906	74.6
25–34	19,096	15,507	81.2	10,841	56.8	13,755	72.0
35–44	27,273	21,882	80.2	15,387	56.4	19,534	71.6
45–54	57,059	46,318	81.2	33,929	59.5	42,109	73.8
≥55	89,352	71,618	80.2	55,966	62.6	66,336	74.2
Subtotal	195,335	157,445	80.6	117,648	60.2	143,640	73.5
Multiracial
13–24	783	656	83.8	485	62.0	533	68.1
25–34	5,401	4,502	83.4	3,191	59.1	3,637	67.3
35–44	5,224	4,403	84.3	3,217	61.6	3,731	71.4
45–54	6,635	5,813	87.6	4,407	66.4	5,118	77.1
≥55	6,600	5,870	88.9	4,723	71.6	5,351	81.1
Subtotal	24,643	21,244	86.2	16,023	65.0	18,370	74.5
All races
13–24	19,520	15,839	81.1	11,485	58.8	12,914	66.2
25–34	105,957	83,584	78.9	59,885	56.5	68,839	65.0
35–44	101,620	78,061	76.8	57,345	56.4	67,123	66.1
45–54	140,157	108,691	77.5	82,520	58.9	97,061	69.3
≥55	161,352	124,497	77.2	98,487	61.0	113,885	70.6
Total	528,606	410,672	77.7	309,723	58.6	359,821	68.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aPerformed ≥3 months apart during 2019.
^bVL test results are from the most recent test during 2019.
^cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^dHispanic/Latino persons can be of any race.

Table 4a. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by selected characteristics—44 states and the District of Columbia
							VL <200 copies/mL
	Persons alive at year-end 2019		Persons with ≥1 CD4 or VL tests		Persons with ≥1 VL tests			Among persons alive at year-end 2019	Among persons with ≥1 CD4 or VL tests	Among persons with ≥1 VL tests
	No.	%^a	No.	%	No.	%	No.	%	%	%
Gender
Male	702,412	75.9	533,401	75.9	513,077	73.0	462,753	65.9	86.8	90.2
Female	212,405	23.0	160,947	75.8	155,442	73.2	136,113	64.1	84.6	87.6
Transgender male-to-female^b	9,699	1.0	8,190	84.4	7,983	82.3	6,503	67.0	79.4	81.5
Transgender female-to-male^b	391	0.0	334	85.4	314	80.3	267	68.3	79.9	85.0
Additional gender identity^c	170	0.0	151	88.8	149	87.6	120	70.6	79.5	80.5
Age at year-end 2018 (yr)
13–24	29,533	3.2	23,615	80.0	22,963	77.8	18,681	63.3	79.1	81.4
25–34	147,061	15.9	114,125	77.6	110,495	75.1	91,988	62.6	80.6	83.3
35–44	175,204	18.9	132,214	75.5	127,584	72.8	110,891	63.3	83.9	86.9
45–54	254,886	27.6	194,838	76.4	187,749	73.7	169,826	66.6	87.2	90.5
≥55	318,393	34.4	238,231	74.8	228,174	71.7	214,370	67.3	90.0	94.0
Race/ethnicity
American Indian/Alaska Native	2,924	0.3	2,236	76.5	2,097	71.7	1,836	62.8	82.1	87.6
Asian^d	13,903	1.5	10,495	75.5	10,160	73.1	9,731	70.0	92.7	95.8
Black/African American	371,711	40.2	273,801	73.7	263,551	70.9	225,899	60.8	82.5	85.7
Hispanic/Latino^e	220,914	23.9	163,537	74.0	158,720	71.8	142,709	64.6	87.3	89.9
Native Hawaiian/other Pacific Islander	815	0.1	602	73.9	579	71.0	529	64.9	87.9	91.4
White	270,980	29.3	215,050	79.4	205,753	75.9	193,402	71.4	89.9	94.0
Multiracial	43,145	4.7	37,243	86.3	36,046	83.5	31,592	73.2	84.8	87.6
Transmission category^f
Male-to-male sexual contact	528,606	57.1	410,672	77.7	395,518	74.8	359,821	68.1	87.6	91.0
Injection drug use	98,290	10.6	66,875	68.0	64,248	65.4	55,906	56.9	83.6	87.0
Male	56,813	6.1	36,326	63.9	34,723	61.1	30,489	53.7	83.9	87.8
Female	41,478	4.5	30,549	73.7	29,525	71.2	25,418	61.3	83.2	86.1
Male-to-male sexual contact and injection drug use	51,307	5.5	40,865	79.6	39,244	76.5	33,657	65.6	82.4	85.8
Heterosexual contact^g	233,549	25.2	174,765	74.8	168,399	72.1	148,842	63.7	85.2	88.4
Male	68,761	7.4	48,995	71.3	47,008	68.4	41,608	60.5	84.9	88.5
Female	164,787	17.8	125,770	76.3	121,391	73.7	107,234	65.1	85.3	88.3
Other^h
Male	6,771	0.7	4,864	71.8	4,697	69.4	3,787	55.9	77.9	80.6
Female	6,554	0.7	4,981	76.0	4,859	74.1	3,742	57.1	75.1	77.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	754,205	81.5	573,250	76.0	552,557	73.3	494,457	65.6	86.3	89.5
Metropolitan areas (pop. 50,000–499,999)	93,099	10.1	72,080	77.4	69,346	74.5	62,051	66.7	86.1	89.5
Nonmetropolitan areas (pop. <50,000)	52,469	5.7	39,948	76.1	37,937	72.3	34,023	64.8	85.2	89.7
Totalⁱ	925,077	100	703,023	76.0	676,965	73.2	605,756	65.5	86.2	89.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aRepresents percentage of the total number for the column.
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to the column total. Data presented based on sex at birth and include transgender persons.
^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Includes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified.
^IIncludes 685 persons of unknown race/ethnicity.

Table 4b. HIV viral suppression during 2019 among persons aged ≥13 years with HIV infection diagnosed by year-end 2018 and alive at year-end 2019, by area of residence—44 states and the District of Columbia
							VL <200 copies/mL
	Persons alive at year-end 2019		Persons with ≥1 CD4 or VL tests		Persons with ≥1 VL tests			Among persons alive at year-end 2019	Among persons with ≥1 CD4 or VL tests	Among persons with ≥1 VL tests
	No.	%^a	No.	%	No.	%	No.	%	%	%
Alabama	13,245	1.4	10,325	78.0	10,034	75.8	8,837	66.7	85.6	88.1
Alaska	700	0.1	616	88.0	606	86.6	552	78.9	89.6	91.1
Arizona	16,537	1.8	12,323	74.5	11,264	68.1	10,276	62.1	83.4	91.2
Arkansas	5,668	0.6	3,721	65.6	3,237	57.1	2,715	47.9	73.0	83.9
California	128,592	13.9	98,773	76.8	94,714	73.7	86,913	67.6	88.0	91.8
Colorado	12,556	1.4	8,427	67.1	8,154	64.9	7,526	59.9	89.3	92.3
Connecticut	10,380	1.1	8,361	80.5	7,681	74.0	7,059	68.0	84.4	91.9
Delaware	3,286	0.4	2,749	83.7	2,721	82.8	2,456	74.7	89.3	90.3
District of Columbia	13,777	1.5	9,463	68.7	9,201	66.8	8,082	58.7	85.4	87.8
Florida	109,195	11.8	84,213	77.1	81,606	74.7	73,187	67.0	86.9	89.7
Georgia	54,031	5.8	39,619	73.3	38,188	70.7	33,270	61.6	84.0	87.1
Hawaii	2,324	0.3	1,925	82.8	1,897	81.6	1,762	75.8	91.5	92.9
Illinois	34,564	3.7	24,366	70.5	22,121	64.0	19,097	55.3	78.4	86.3
Indiana	11,145	1.2	8,070	72.4	7,434	66.7	6,705	60.2	83.1	90.2
Iowa	2,785	0.3	2,452	88.0	2,434	87.4	2,275	81.7	92.8	93.5
Louisiana	20,425	2.2	16,185	79.2	16,002	78.3	13,952	68.3	86.2	87.2
Maine	1,613	0.2	1,368	84.8	1,362	84.4	1,307	81.0	95.5	96.0
Maryland	32,466	3.5	23,932	73.7	23,580	72.6	21,083	64.9	88.1	89.4
Massachusetts^b	20,514	2.2	16,162	78.8	15,573	75.9	14,581	71.1	90.2	93.6
Michigan	15,903	1.7	13,332	83.8	12,994	81.7	11,713	73.7	87.9	90.1
Minnesota	8,532	0.9	6,708	78.6	6,399	75.0	5,934	69.5	88.5	92.7
Mississippi^b	9,356	1.0	6,830	73.0	6,066	64.8	5,043	53.9	73.8	83.1
Missouri	12,320	1.3	9,630	78.2	9,190	74.6	8,277	67.2	86.0	90.1
Montana	638	0.1	569	89.2	561	87.9	535	83.9	94.0	95.4
Nebraska	2,151	0.2	1,652	76.8	1,494	69.5	1,355	63.0	82.0	90.7
Nevada^b	10,228	1.1	7,047	68.9	6,585	64.4	5,911	57.8	83.9	89.8
New Hampshire	1,273	0.1	1,042	81.9	1,028	80.8	965	75.8	92.6	93.9
New Mexico	3,582	0.4	2,664	74.4	2,393	66.8	2,162	60.4	81.2	90.3
New York	124,135	13.4	92,597	74.6	91,860	74.0	81,751	65.9	88.3	89.0
North Carolina	31,640	3.4	24,495	77.4	23,907	75.6	21,291	67.3	86.9	89.1
North Dakota^b	456	0.0	371	81.4	363	79.6	324	71.1	87.3	89.3
Ohio	22,204	2.4	16,766	75.5	15,723	70.8	13,969	62.9	83.3	88.8
Oklahoma	6,033	0.7	4,244	70.3	4,043	67.0	3,521	58.4	83.0	87.1
Oregon	7,080	0.8	6,313	89.2	6,067	85.7	5,701	80.5	90.3	94.0
Rhode Island	2,584	0.3	2,206	85.4	2,185	84.6	2,047	79.2	92.8	93.7
South Carolina	16,917	1.8	13,701	81.0	13,352	78.9	11,967	70.7	87.3	89.6
South Dakota	618	0.1	506	81.9	361	58.4	321	51.9	63.4	88.9
Tennessee	16,957	1.8	13,929	82.1	13,227	78.0	11,383	67.1	81.7	86.1
Texas	90,852	9.8	68,574	75.5	65,056	71.6	56,315	62.0	82.1	86.6
Utah	2,947	0.3	2,287	77.6	2,255	76.5	2,092	71.0	91.5	92.8
Virginia	22,870	2.5	15,972	69.8	15,773	69.0	14,462	63.2	90.5	91.7
Washington	13,539	1.5	11,688	86.3	11,556	85.4	10,861	80.2	92.9	94.0
West Virginia	1,847	0.2	1,373	74.3	1,318	71.4	1,182	64.0	86.1	89.7
Wisconsin	6,279	0.7	5,204	82.9	5,160	82.2	4,813	76.7	92.5	93.3
Wyoming	333	0.0	273	82.0	240	72.1	226	67.9	82.8	94.2
Total	925,077	100	703,023	76.0	676,965	73.2	605,756	65.5	86.2	89.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2019 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2019. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Vermont, and Puerto Rico.

^aRepresents percentage of the total number for the column.
^bData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 5. Prevalence-based HIV care continuum for persons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at year-end 2019, by selected characteristics—United States
	Persons with HIV infection alive at year-end 2019^a	Persons with diagnosed HIV infection alive at year-end 2019^b		Receipt of care^c		Retention in care^c		Viral suppression^c
	Total No.	No.	%	No.	%	No.	%	No.	%
Sex at birth
Male	925,800	794,128	86	604,000	65	458,500	49	523,300	57
Female	263,900	237,063	90	179,700	68	137,300	52	151,900	58
Age at year-end 2019 (yr)
13–24	45,900	25,581	56	20,500	45	15,000	33	16,200	35
25–34	218,700	156,378	72	121,300	55	87,100	40	97,800	45
35–44	228,000	192,894	85	145,600	64	107,000	47	122,100	54
45–54	290,000	268,039	92	204,900	71	156,300	54	178,600	62
≥55	407,100	388,299	95	290,500	71	231,000	57	261,400	64
Race/ethnicity
American Indian/Alaska Native	4,000	3,185	80	2,400	61	1,800	45	2,000	50
Asian^d	17,700	15,309	87	11,600	65	9,000	51	10,700	61
Black/African American	479,300	415,003	87	305,700	64	230,200	48	252,200	53
Hispanic/Latino^e	294,200	246,078	84	182,200	62	144,300	49	159,000	54
Native Hawaiian/other Pacific Islander	1,100	906	84	670	61	480	44	590	53
White	338,600	301,927	89	239,600	71	178,200	53	215,500	64
Multiracial	54,100	48,063	89	41,500	77	31,700	59	35,200	65
Transmission category^f
Male-to-male sexual contact	692,900	587,555	85	456,500	66	344,300	50	399,900	58
Injection drug use
Male	72,900	67,603	93	43,200	59	33,900	46	36,300	50
Female	51,900	48,660	94	35,800	69	27,500	53	29,800	57
Male-to-male sexual contact and injection drug use	61,800	56,720	92	45,200	73	34,800	56	37,200	60
Heterosexual contact^g
Male	96,300	80,351	83	57,300	59	44,300	46	48,600	50
Female	210,700	187,127	89	142,800	68	108,900	52	121,800	58
Total^h	1,189,700	1,031,191	87	783,700	66	596,700	50	675,200	57

Abbreviation: RSE, relative standard error (footnotes only).

^aEstimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis (i.e., persons living with diagnosed or undiagnosed HIV infection). Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤ 1,000 to reflect model uncertainty. Estimates with a relative standard error 30%-50% are preceded by an asterisk (*) and should be interpreted with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and replaced by an ellipsis (…). Data previously published in the HIV Surveillance Supplemental Report 2021;26(No. 1). https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
^bReported to National HIV Surveillance System. Data previously published in the HIV Surveillance Supplemental Report 2021;26(No. 1). https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
^cEstimates are the result of extrapolating data from the 45 jurisdictions with complete CD4 and viral load reporting by applying the percentage in the 45 jurisdictions (found in Tables 3a and 4a) to the total number of people living with diagnosed HIV in the United States. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^gHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

Table 6a. Stage 3 (AIDS) at time of HIV diagnosis among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2015–2019—United States
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	31,748	6,786	21.4	31,298	6,614	21.1	30,411	6,321	20.8	29,699	6,148	20.7	28,781	5,899	20.5
Female	7,324	1,723	23.5	7,457	1,665	22.3	7,248	1,604	22.1	7,025	1,523	21.7	6,868	1,412	20.6
Transgender male-to-female^b	589	71	12.1	639	89	13.9	581	79	13.6	596	80	13.4	623	86	13.8
Transgender female-to-male^b	32	1	3.1	21	3	14.3	36	5	13.9	48	2	4.2	46	5	10.9
Additional gender identity^c	10	0	0.0	12	3	25.0	13	2	15.4	14	1	7.1	19	0	0.0
Age at diagnosis (yr)
13–24	9,070	751	8.3	8,652	756	8.7	8,281	742	9.0	7,835	715	9.1	7,588	633	8.3
25–34	13,010	2,159	16.6	13,602	2,228	16.4	13,361	2,151	16.1	13,382	2,126	15.9	13,014	2,131	16.4
35–44	7,607	2,134	28.1	7,457	2,022	27.1	7,241	1,875	25.9	7,181	1,841	25.6	7,068	1,778	25.2
45–54	6,288	2,145	34.1	5,896	1,966	33.3	5,569	1,886	33.9	5,233	1,749	33.4	4,866	1,545	31.8
≥55	3,728	1,392	37.3	3,820	1,402	36.7	3,837	1,357	35.4	3,751	1,323	35.3	3,801	1,315	34.6
Race/ethnicity
American Indian/Alaska Native	170	39	22.9	217	51	23.5	206	45	21.8	182	29	15.9	209	27	12.9
Asian	907	202	22.3	919	218	23.7	915	229	25.0	849	226	26.6	732	181	24.7
Black/African American	16,670	3,407	20.4	16,493	3,356	20.3	15,931	3,195	20.1	15,441	3,035	19.7	15,299	2,949	19.3
Hispanic/Latino^d	10,316	2,266	22.0	10,601	2,302	21.7	10,460	2,212	21.1	10,530	2,279	21.6	10,112	2,155	21.3
Native Hawaiian/other Pacific Islander	66	16	24.2	40	8	20.0	51	13	25.5	64	13	20.3	66	11	16.7
White	10,051	2,329	23.2	9,753	2,170	22.2	9,546	2,080	21.8	9,293	1,976	21.3	9,006	1,895	21.0
Multiracial	1,523	322	21.1	1,404	269	19.2	1,180	237	20.1	1,023	196	19.2	913	184	20.2
Transmission category^e
Male-to-male sexual contact	26,273	5,063	19.3	25,947	4,974	19.2	25,337	4,820	19.0	24,556	4,723	19.2	23,866	4,489	18.8
Injection drug use
Male	1,295	382	29.5	1,203	336	27.9	1,301	343	26.4	1,407	326	23.2	1,375	339	24.7
Female	1,033	213	20.6	1,000	201	20.1	1,053	205	19.5	1,084	220	20.3	1,106	193	17.5
Male-to-male sexual contact and injection drug use	1,499	282	18.8	1,498	257	17.1	1,421	215	15.1	1,408	200	14.2	1,457	245	16.8
Heterosexual contact^f
Male	3,249	1,117	34.4	3,275	1,129	34.5	2,913	1,015	34.8	2,903	972	33.5	2,685	899	33.5
Female	6,298	1,504	23.9	6,437	1,456	22.6	6,198	1,398	22.5	5,958	1,295	21.7	5,787	1,218	21.0
Other^g
Male	31	12	39.5	24	10	43.4	34	9	27.1	35	8	23.1	37	13	36.2
Female	25	7	26.2	43	11	25.9	33	6	19.6	32	9	29.2	25	6	24.4
Region of residence
Northeast	6,440	1,519	23.6	6,203	1,364	22.0	6,000	1,292	21.5	5,562	1,260	22.7	5,268	1,158	22.0
Midwest	5,212	1,144	21.9	5,154	1,165	22.6	5,086	1,074	21.1	4,932	1,114	22.6	4,750	981	20.7
South	20,331	4,336	21.3	20,220	4,284	21.2	19,658	4,170	21.2	19,364	3,902	20.2	19,100	3,856	20.2
West	7,720	1,582	20.5	7,850	1,561	19.9	7,545	1,475	19.5	7,524	1,478	19.6	7,219	1,407	19.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	32,295	6,734	20.9	32,075	6,576	20.5	31,127	6,287	20.2	30,352	6,070	20.0	29,056	5,752	19.8
Metropolitan areas (pop. 50,000–499,999)	4,560	1,143	25.1	4,701	1,124	23.9	4,683	1,079	23.0	4,616	1,063	23.0	4,418	974	22.0
Nonmetropolitan areas (pop. <50,000)	2,507	655	26.1	2,323	628	27.0	2,239	596	26.6	2,312	607	26.3	2,262	571	25.2
Total	39,703	8,581	21.6	39,427	8,374	21.2	38,289	8,011	20.9	37,382	7,754	20.7	36,337	7,402	20.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis.

^aBased on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dHispanic/Latino persons can be of any race.
^eData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified.

Table 6b. Stage 3 (AIDS) at time of HIV diagnosis among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	32,218	6,882	21.4	31,744	6,728	21.2	30,780	6,386	20.7	30,066	6,230	20.7	29,101	5,973	20.5
Female	7,436	1,749	23.5	7,562	1,687	22.3	7,342	1,628	22.2	7,106	1,540	21.7	6,949	1,439	20.7
Transgender male-to-female^b	593	72	12.1	641	89	13.9	583	79	13.6	597	81	13.6	625	86	13.8
Transgender female-to-male^b	32	1	3.1	21	3	14.3	36	5	13.9	48	2	4.2	46	5	10.9
Additional gender identity^c	10	0	0.0	12	3	25.0	13	2	15.4	14	1	7.1	19	0	0.0
Age at diagnosis (yr)
13–24	9,158	760	8.3	8,737	766	8.8	8,359	747	8.9	7,909	720	9.1	7,648	639	8.4
25–34	13,168	2,182	16.6	13,737	2,246	16.4	13,490	2,169	16.1	13,517	2,144	15.9	13,127	2,154	16.4
35–44	7,742	2,162	27.9	7,586	2,058	27.1	7,331	1,900	25.9	7,259	1,861	25.6	7,147	1,794	25.1
45–54	6,413	2,185	34.1	6,001	2,003	33.4	5,662	1,908	33.7	5,327	1,778	33.4	4,931	1,574	31.9
≥55	3,808	1,415	37.2	3,919	1,437	36.7	3,912	1,376	35.2	3,819	1,351	35.4	3,887	1,342	34.5
Race/ethnicity
American Indian/Alaska Native	170	39	22.9	217	51	23.5	206	45	21.8	182	29	15.9	209	27	12.9
Asian	911	202	22.2	920	218	23.7	918	231	25.2	853	226	26.5	738	184	24.9
Black/African American	16,679	3,412	20.5	16,499	3,358	20.4	15,935	3,196	20.1	15,448	3,036	19.7	15,305	2,951	19.3
Hispanic/Latino^d	10,883	2,380	21.9	11,139	2,433	21.8	10,910	2,296	21.0	10,960	2,375	21.7	10,494	2,249	21.4
Native Hawaiian/other Pacific Islander	69	18	26.1	46	10	21.7	54	15	27.8	66	15	22.7	70	12	17.1
White	10,053	2,331	23.2	9,755	2,171	22.3	9,550	2,080	21.8	9,297	1,977	21.3	9,011	1,896	21.0
Multiracial	1,524	322	21.1	1,404	269	19.2	1,181	237	20.1	1,025	196	19.1	913	184	20.2
Transmission category^e
Male-to-male sexual contact	26,585	5,121	19.3	26,244	5,027	19.2	25,580	4,858	19.0	24,819	4,770	19.2	24,084	4,531	18.8
Injection drug use
Male	1,348	391	29.0	1,241	353	28.4	1,333	350	26.2	1,432	335	23.4	1,397	346	24.8
Female	1,040	214	20.6	1,011	203	20.1	1,062	205	19.3	1,086	220	20.3	1,111	196	17.7
Male-to-male sexual contact and injection drug use	1,522	286	18.8	1,510	262	17.3	1,432	216	15.1	1,420	206	14.5	1,468	248	16.9
Heterosexual contact^f
Male	3,335	1,144	34.3	3,377	1,168	34.6	2,997	1,034	34.5	2,970	993	33.4	2,754	921	33.4
Female	6,402	1,529	23.9	6,530	1,476	22.6	6,283	1,422	22.6	6,037	1,312	21.7	5,863	1,242	21.2
Other^g
Male	31	12	39.7	24	10	43.4	34	9	27.1	35	8	23.3	37	13	36.2
Female	25	7	26.8	43	11	25.8	33	6	19.5	32	9	29.2	25	6	24.4
Region of residence
Northeast	6,440	1,519	23.6	6,203	1,364	22.0	6,000	1,292	21.5	5,562	1,260	22.7	5,268	1,158	22.0
Midwest	5,212	1,144	21.9	5,154	1,165	22.6	5,086	1,074	21.1	4,932	1,114	22.6	4,750	981	20.7
South	20,331	4,336	21.3	20,220	4,284	21.2	19,658	4,170	21.2	19,364	3,902	20.2	19,100	3,856	20.2
West	7,720	1,582	20.5	7,850	1,561	19.9	7,545	1,475	19.5	7,524	1,478	19.6	7,219	1,407	19.5
U.S. dependent areas	586	123	21.0	553	136	24.6	465	89	19.1	449	100	22.3	403	101	25.1
Total	40,289	8,704	21.6	39,980	8,510	21.3	38,754	8,100	20.9	37,831	7,854	20.8	36,740	7,503	20.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis.

^aBased on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dHispanic/Latino persons can be of any race.
^eData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^fHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified.

Table 6c. Stage 3 (AIDS) at time of HIV diagnosis among persons aged ≥13 years, by year of diagnosis and area of residence, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Alabama	663	161	24.3	653	143	21.9	650	142	21.8	607	126	20.8	638	139	21.8
Alaska	25	5	20.0	37	6	16.2	29	7	24.1	23	4	17.4	27	2	7.4
Arizona	689	147	21.3	714	144	20.2	727	135	18.6	753	159	21.1	761	133	17.5
Arkansas	271	60	22.1	315	69	21.9	287	50	17.4	278	60	21.6	287	72	25.1
California	5,029	950	18.9	5,067	970	19.1	4,806	917	19.1	4,715	876	18.6	4,354	818	18.8
Colorado	377	97	25.7	421	84	20.0	435	79	18.2	402	96	23.9	461	102	22.1
Connecticut	276	71	25.7	256	67	26.2	274	65	23.7	259	64	24.7	213	60	28.2
Delaware	104	29	27.9	111	35	31.5	126	32	25.4	91	22	24.2	93	20	21.5
District of Columbia	365	54	14.8	351	58	16.5	316	40	12.7	281	43	15.3	255	37	14.5
Florida	4,595	980	21.3	4,651	985	21.2	4,557	973	21.4	4,530	927	20.5	4,378	917	20.9
Georgia	2,627	527	20.1	2,526	469	18.6	2,596	568	21.9	2,482	494	19.9	2,439	493	20.2
Hawaii	117	23	19.7	77	11	14.3	77	13	16.9	72	15	20.8	65	13	20.0
Idaho	40	14	35.0	46	7	15.2	46	11	23.9	37	15	40.5	28	13	46.4
Illinois	1,547	329	21.3	1,483	312	21.0	1,367	290	21.2	1,374	279	20.3	1,252	236	18.8
Indiana	632	121	19.1	489	108	22.1	515	125	24.3	509	129	25.3	486	100	20.6
Iowa	124	46	37.1	132	31	23.5	125	27	21.6	116	25	21.6	100	21	21.0
Kansas	155	35	22.6	147	34	23.1	119	25	21.0	157	42	26.8	131	25	19.1
Kentucky	340	79	23.2	338	109	32.2	365	88	24.1	378	76	20.1	326	70	21.5
Louisiana	1,095	241	22.0	1,108	259	23.4	996	229	23.0	961	182	18.9	881	186	21.1
Maine	47	13	27.7	53	12	22.6	29	11	37.9	30	10	33.3	30	11	36.7
Maryland	1,168	252	21.6	1,097	228	20.8	1,020	249	24.4	991	203	20.5	918	208	22.7
Massachusetts	598	138	23.1	640	139	21.7	608	124	20.4	649	150	23.1	535	109	20.4
Michigan	723	162	22.4	746	178	23.9	773	154	19.9	715	168	23.5	674	148	22.0
Minnesota	296	73	24.7	297	67	22.6	277	75	27.1	288	67	23.3	274	63	23.0
Mississippi	502	118	23.5	427	118	27.6	428	115	26.9	476	130	27.3	477	120	25.2
Missouri	463	94	20.3	512	120	23.4	502	84	16.7	449	96	21.4	488	89	18.2
Montana	19	5	26.3	20	3	15.0	32	6	18.8	23	5	21.7	25	4	16.0
Nebraska	78	22	28.2	75	18	24.0	88	13	14.8	79	26	32.9	81	21	25.9
Nevada	477	109	22.9	509	114	22.4	494	106	21.5	501	97	19.4	512	114	22.3
New Hampshire	25	2	8.0	39	11	28.2	32	5	15.6	38	10	26.3	31	4	12.9
New Jersey	1,192	312	26.2	1,188	277	23.3	1,123	241	21.5	1,021	235	23.0	1,057	234	22.1
New Mexico	137	32	23.4	146	32	21.9	141	30	21.3	135	32	23.7	156	24	15.4
New York	3,051	657	21.5	2,820	571	20.2	2,729	569	20.9	2,449	542	22.1	2,330	496	21.3
North Carolina	1,328	292	22.0	1,388	274	19.7	1,295	264	20.4	1,186	206	17.4	1,365	213	15.6
North Dakota	20	9	45.0	46	12	26.1	38	10	26.3	36	5	13.9	40	9	22.5
Ohio	925	196	21.2	955	227	23.8	983	212	21.6	973	224	23.0	980	209	21.3
Oklahoma	314	69	22.0	294	74	25.2	299	63	21.1	278	61	21.9	320	50	15.6
Oregon	223	67	30.0	228	54	23.7	203	49	24.1	230	52	22.6	199	49	24.6
Pennsylvania	1,173	303	25.8	1,131	265	23.4	1,100	244	22.2	1,023	219	21.4	989	228	23.1
Rhode Island	64	19	29.7	71	19	26.8	85	24	28.2	75	22	29.3	72	14	19.4
South Carolina	670	174	26.0	747	179	24.0	706	180	25.5	712	175	24.6	680	164	24.1
South Dakota	24	11	45.8	43	12	27.9	39	8	20.5	29	7	24.1	33	8	24.2
Tennessee	736	129	17.5	716	115	16.1	721	124	17.2	746	146	19.6	773	134	17.3
Texas	4,529	964	21.3	4,527	958	21.2	4,356	861	19.8	4,422	859	19.4	4,302	842	19.6
Utah	123	25	20.3	139	24	17.3	113	22	19.5	121	17	14.0	135	27	20.0
Vermont	14	4	28.6	5	3	60.0	20	9	45.0	18	8	44.4	11	2	18.2
Virginia	953	181	19.0	903	191	21.2	863	170	19.7	861	171	19.9	822	168	20.4
Washington	447	105	23.5	425	104	24.5	432	96	22.2	500	109	21.8	483	106	21.9
West Virginia	71	26	36.6	68	20	29.4	77	22	28.6	84	21	25.0	146	23	15.8
Wisconsin	225	46	20.4	229	46	20.1	260	51	19.6	207	46	22.2	211	52	24.6
Wyoming	17	3	17.6	21	8	38.1	10	4	40.0	12	1	8.3	13	2	15.4
Subtotal	39,703	8,581	21.6	39,427	8,374	21.2	38,289	8,011	20.9	37,382	7,754	20.7	36,337	7402	20.4
U.S. dependent areas
American Samoa	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Guam	6	2	33.3	4	2	50.0	6	4	66.7	7	3	42.9	10	3	30.0
Northern Mariana Islands	2	1	50.0	0	0	0.0	1	0	0.0	1	0	0.0	2	1	50.0
Puerto Rico	565	114	20.2	535	129	24.1	450	84	18.7	431	96	22.3	383	94	24.5
Republic of Palau	1	0	0.0	2	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
U.S. Virgin Islands	12	6	50.0	12	5	41.7	8	1	12.5	10	1	10.0	8	3	37.5
Subtotal	586	123	21.0	553	136	24.6	465	89	19.1	449	100	22.3	403	101	25.1
Total	40,289	8,704	21.6	39,980	8,510	21.3	38,754	8,100	20.9	37,831	7,854	20.8	36,740	7,503	20.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis.

^aBased on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 6d. Stage 3 (AIDS) at time of HIV diagnosis among persons aged ≥13 years, by race/ethnicity and area of residence, 2019—United States
	Black/African American			Hispanic/Latino^a			White			Other^b
		Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Alabama	457	104	22.8	13	2	15.4	152	31	20.4	16	2	12.5
Alaska	5	1	20.0	4	0	0.0	12	1	8.3	6	0	0.0
Arizona	128	22	17.2	321	59	18.4	248	43	17.3	64	9	14.1
Arkansas	139	32	23.0	17	6	35.3	121	29	24.0	10	5	50.0
California	742	95	12.8	2,180	446	20.5	1,072	195	18.2	360	82	22.8
Colorado	73	17	23.3	170	40	23.5	202	42	20.8	16	3	18.8
Connecticut	96	27	28.1	51	11	21.6	57	16	28.1	9	6	66.7
Delaware	61	13	21.3	8	2	25.0	22	5	22.7	2	0	0.0
District of Columbia	195	25	12.8	30	8	26.7	19	2	10.5	11	2	18.2
Florida	1,692	389	23.0	1,570	301	19.2	1,013	203	20.0	103	24	23.3
Georgia	1,753	362	20.7	237	45	19.0	366	69	18.9	83	17	20.5
Hawaii	1	0	0.0	12	1	8.3	13	2	15.4	39	10	25.6
Idaho	2	1	50.0	10	6	60.0	15	5	33.3	1	1	100
Illinois	651	114	17.5	300	63	21.0	233	48	20.6	68	11	16.2
Indiana	215	41	19.1	68	8	11.8	186	48	25.8	17	3	17.6
Iowa	32	11	34.4	12	1	8.3	47	9	19.1	9	0	0.0
Kansas	38	5	13.2	26	7	26.9	60	12	20.0	7	1	14.3
Kentucky	91	13	14.3	28	7	25.0	195	42	21.5	12	8	66.7
Louisiana	578	118	20.4	81	22	27.2	206	42	20.4	16	4	25.0
Maine	11	4	36.4	2	1	50.0	15	5	33.3	2	1	50.0
Maryland	672	144	21.4	102	32	31.4	99	24	24.2	45	8	17.8
Massachusetts	171	47	27.5	145	24	16.6	173	28	16.2	46	10	21.7
Michigan	387	67	17.3	54	15	27.8	215	63	29.3	18	3	16.7
Minnesota	98	27	27.6	38	9	23.7	106	23	21.7	32	4	12.5
Mississippi	364	86	23.6	19	7	36.8	87	25	28.7	7	2	28.6
Missouri	235	36	15.3	46	4	8.7	185	43	23.2	22	6	27.3
Montana	0	0	0.0	3	0	0.0	20	4	20.0	2	0	0.0
Nebraska	21	7	33.3	16	6	37.5	36	6	16.7	8	2	25.0
Nevada	172	30	17.4	152	35	23.0	157	43	27.4	31	6	19.4
New Hampshire	4	0	0.0	5	2	40.0	17	2	11.8	5	0	0.0
New Jersey	426	86	20.2	389	90	23.1	185	41	22.2	57	17	29.8
New Mexico	9	0	0.0	84	15	17.9	34	6	17.6	29	3	10.3
New York	951	182	19.1	864	190	22.0	341	72	21.1	174	52	29.9
North Carolina	843	132	15.7	160	27	16.9	299	52	17.4	63	2	3.2
North Dakota	19	4	21.1	4	0	0.0	17	5	29.4	0	0	0.0
Ohio	468	95	20.3	60	17	28.3	405	91	22.5	47	6	12.8
Oklahoma	91	15	16.5	46	9	19.6	125	21	16.8	58	5	8.6
Oregon	22	5	22.7	36	7	19.4	128	33	25.8	13	4	30.8
Pennsylvania	472	85	18.0	180	43	23.9	295	88	29.8	42	12	28.6
Rhode Island	16	3	18.8	16	1	6.3	35	9	25.7	5	1	20.0
South Carolina	455	97	21.3	47	17	36.2	161	48	29.8	17	2	11.8
South Dakota	4	1	25.0	4	1	25.0	12	4	33.3	13	2	15.4
Tennessee	407	60	14.7	75	18	24.0	265	50	18.9	26	6	23.1
Texas	1,280	189	14.8	2,129	491	23.1	698	131	18.8	195	31	15.9
Utah	9	0	0.0	47	10	21.3	67	15	22.4	12	2	16.7
Vermont	2	0	0.0	1	0	0.0	7	1	14.3	1	1	100
Virginia	525	110	21.0	88	15	17.0	177	36	20.3	32	7	21.9
Washington	103	23	22.3	119	26	21.8	213	43	20.2	48	14	29.2
West Virginia	15	3	20.0	3	0	0.0	120	18	15.0	8	2	25.0
Wisconsin	98	21	21.4	35	8	22.9	66	20	30.3	12	3	25.0
Wyoming	0	0	0.0	5	0	0.0	7	1	14.3	1	1	100
Total	15,299	2,949	19.3	10,112	2,155	21.3	9,006	1,895	21.0	1,920	403	21.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis.

^aHispanic/Latino persons can be of any race.
^bIncludes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and Multiracial persons.
^cBased on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 7a. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2015–2019—United States
	2015			2016			2017			2018			2019
	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a
Gender
Male	11,847	–	16.4	12,240	–	16.4	12,256	–	16.0	12,068	–	15.4	11,699	–	14.6
Female	3,890	–	16.9	4,024	–	17.1	3,991	–	16.7	3,985	–	16.4	3,624	–	14.7
Transgender male-to-female^b	108	–	11.9	121	–	12.6	104	–	10.3	119	–	11.2	134	–	12.0
Transgender female-to-male^b	5	–	15.5	2	–	5.9	4	–	10.8	3	–	7.1	5	–	10.8
Additional gender identity^c	1	–	7.4	0	–	0.0	1	–	6.1	1	–	5.5	1	–	5.0
Age at death (yr)
13–24	161	0.3	3.4	167	0.3	3.7	150	0.3	3.4	130	0.3	3.1	128	0.3	3.2
25–34	990	2.2	6.7	1,106	2.5	7.1	1,047	2.3	6.5	1,027	2.3	6.2	1,039	2.3	6.0
35–44	2,041	5.0	10.2	1,966	4.9	10.0	1,835	4.5	9.4	1,764	4.3	9.0	1,681	4.0	8.5
45–54	4,937	11.5	15.6	4,649	10.9	14.8	4,469	10.6	14.5	4,180	10.1	14.0	3,462	8.5	12.1
≥55	7,722	8.7	30.5	8,499	9.4	30.4	8,855	9.6	29.0	9,075	9.6	27.2	9,153	9.5	25.2
Race/ethnicity
American Indian/Alaska Native	61	3.2	23.2	47	2.4	16.8	46	2.4	15.5	48	2.4	15.5	51	2.6	15.6
Asian^d	81	0.6	6.7	101	0.7	7.8	88	0.6	6.3	85	0.5	5.8	95	0.6	6.1
Black/African American	7,126	21.8	18.2	7,244	22.0	18.1	7,196	21.6	17.5	6,977	20.7	16.6	6,633	19.5	15.5
Hispanic/Latino^e	2,518	5.9	11.6	2,628	6.0	11.6	2,688	6.0	11.4	2,821	6.1	11.6	2,702	5.7	10.7
Native Hawaiian/other Pacific Islander	7	1.6	9.4	14	3.0	18.1	9	1.9	11.1	13	2.7	15.0	14	2.9	15.2
White	5,021	2.9	17.3	5,320	3.1	18.0	5,253	3.1	17.5	5,147	3.0	16.9	4,922	2.9	16.0
Multiracial	1,031	24.3	20.9	1,030	23.4	20.7	1,074	23.6	21.5	1,085	23.1	21.7	1,042	21.5	20.9
Transmission category^f
Male adult or adolescent^g
Male-to-male sexual contact	6,566	–	12.6	6,897	–	12.8	7,005	–	12.5	6,876	–	11.9	6,855	–	11.5
Injection drug use	2,288	–	31.5	2,272	–	31.7	2,168	–	30.6	2,187	–	31.1	1,965	–	28.2
Male-to-male sexual contact and injection drug use	1,400	–	24.3	1,397	–	24.2	1,370	–	23.7	1,427	–	24.6	1,304	–	22.5
Heterosexual contact^h	1,597	–	20.9	1,692	–	21.7	1,711	–	21.5	1,589	–	19.7	1,614	–	19.7
Otherⁱ	104	–	14.1	102	–	13.7	107	–	14.1	108	–	14.1	97	–	12.5
Subtotal	11,956	9.1	16.3	12,361	9.4	16.4	12,361	9.3	16.0	12,187	9.1	15.4	11,834	8.8	14.6
Female adult or adolescent^g
Injection drug use	1,353	–	26.6	1,384	–	27.4	1,373	–	27.3	1,319	–	26.4	1,221	–	24.5
Heterosexual contact^h	2,468	–	14.2	2,567	–	14.4	2,551	–	14.0	2,607	–	14.0	2,352	–	12.4
Otherⁱ	74	–	11.1	74	–	10.8	71	–	10.1	63	–	8.8	56	–	7.6
Subtotal	3,895	2.8	16.9	4,026	2.9	17.1	3,995	2.9	16.7	3,989	2.8	16.4	3,629	2.6	14.7
Region of residence
Northeast	3,612	7.6	15.7	3,711	7.8	15.9	3,699	7.7	15.7	3,534	7.4	14.9	3,450	7.2	14.4
Midwest	1,821	3.2	16.0	1,857	3.3	15.8	1,910	3.3	15.8	2,000	3.5	16.1	1,849	3.2	14.6
South	7,810	7.8	18.0	8,055	7.9	18.1	8,008	7.8	17.5	7,848	7.5	16.7	7,517	7.1	15.6
West	2,608	4.1	13.9	2,764	4.3	14.3	2,739	4.3	13.7	2,794	4.3	13.6	2,647	4.0	12.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	9,823	5.4	12.6	10,274	5.6	12.9	10,385	5.6	12.6	10,114	5.4	12.1	10,776	5.7	12.5
Metropolitan areas (pop. 50,000–499,999)	1,498	3.2	16.0	1,362	2.9	14.1	1,530	3.2	15.3	1,491	3.1	14.5	1,596	3.3	14.9
Nonmetropolitan areas (pop. <50,000)	887	2.3	16.9	895	2.3	16.6	952	2.5	17.1	860	2.2	15.1	927	2.4	15.8
Total^j	15,851	5.9	16.4	16,387	6.1	16.6	16,356	6.0	16.1	16,176	5.9	15.6	15,463	5.6	14.6

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
^gData presented based on sex at birth and include transgender persons.
^hHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or risk factor not reported or not identified.
^jIncludes persons of unknown race/ethnicity.

Table 7b. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a
Gender
Male	12,149	–	16.5	12,564	–	16.6	12,556	–	16.2	12,361	–	15.6	11,968	–	14.7
Female	3,997	–	16.9	4,119	–	17.2	4,099	–	16.8	4,061	–	16.4	3,705	–	14.7
Transgender male-to-female^b	108	–	11.9	121	–	12.6	106	–	10.5	120	–	11.3	136	–	12.2
Transgender female-to-male^b	5	–	15.5	2	–	5.9	4	–	10.7	3	–	7.1	5	–	10.7
Additional gender identity^c	1	–	7.4	0	–	0.0	1	–	6.1	1	–	5.5	1	–	5.0
Age at death (yr)
13–24	163	0.3	3.4	172	0.3	3.8	152	0.3	3.5	134	0.3	3.2	130	0.3	3.2
25–34	1,016	2.3	6.8	1,121	2.5	7.2	1,068	2.3	6.6	1,047	2.3	6.2	1,058	2.3	6.1
35–44	2,097	5.1	10.3	2,029	5.0	10.2	1,885	4.6	9.5	1,814	4.4	9.2	1,735	4.1	8.7
45–54	5,086	11.7	15.8	4,772	11.0	14.9	4,599	10.8	14.7	4,269	10.2	14.1	3,571	8.6	12.3
≥55	7,898	8.8	30.5	8,712	9.5	30.6	9,062	9.7	29.0	9,282	9.7	27.2	9,321	9.5	25.2
Race/ethnicity
American Indian/Alaska Native	61	–	23.1	47	–	16.8	46	–	15.5	48	–	15.5	51	–	15.6
Asian^d	82	–	6.8	101	–	7.8	88	–	6.3	85	–	5.7	95	–	6.1
Black/African American	7,132	–	18.2	7,253	–	18.1	7,201	–	17.5	6,977	–	16.6	6,634	–	15.5
Hispanic/Latino^e	2,918	–	12.5	3,034	–	12.5	3,092	–	12.3	3,185	–	12.3	3,047	–	11.4
Native Hawaiian/other Pacific Islander	8	–	10.4	16	–	19.8	9	–	10.6	16	–	17.7	17	–	17.7
White	5,021	–	17.3	5,321	–	18.0	5,254	–	17.5	5,148	–	16.9	4,923	–	16.0
Multiracial	1,032	–	20.9	1,031	–	20.7	1,074	–	21.5	1,087	–	21.8	1,044	–	20.9
Transmission category^f
Male adult or adolescent^g
Male-to-male sexual contact	6,645	–	12.7	6,976	–	12.8	7,077	–	12.6	6,957	–	12.0	6,926	–	11.6
Injection drug use	2,421	–	31.6	2,403	–	31.8	2,299	–	30.9	2,309	–	31.3	2,085	–	28.6
Male-to-male sexual contact and injection drug use	1,429	–	24.4	1,428	–	24.3	1,395	–	23.8	1,448	–	24.7	1,327	–	22.6
Heterosexual contact^h	1,656	–	21.0	1,769	–	21.9	1,784	–	21.8	1,651	–	19.8	1,668	–	19.8
Otherⁱ	107	–	14.1	108	–	14.2	108	–	13.9	115	–	14.7	99	–	12.5
Subtotal	12,258	9.3	16.4	12,685	9.5	16.6	12,663	9.4	16.1	12,481	9.2	15.5	12,105	8.9	14.7
Female adult or adolescent^g
Injection drug use	1,377	–	26.5	1,419	–	27.5	1,408	–	27.4	1,352	–	26.5	1,251	–	24.6
Heterosexual contact^h	2,549	–	14.4	2,624	–	14.4	2,623	–	14.1	2,648	–	14.0	2,401	–	12.4
Otherⁱ	76	–	11.0	77	–	11.0	72	–	10.0	65	–	8.9	58	–	7.8
Subtotal	4,002	2.9	16.9	4,121	2.9	17.1	4,103	2.9	16.8	4,065	2.9	16.4	3,710	2.6	14.7
Region of residence
Northeast	3,612	7.6	15.7	3,711	7.8	15.9	3,699	7.7	15.7	3,534	7.4	14.9	3,450	7.2	14.4
Midwest	1,821	3.2	16.0	1,857	3.3	15.8	1,910	3.3	15.8	2,000	3.5	16.1	1,849	3.2	14.6
South	7,810	7.8	18.0	8,055	7.9	18.1	8,008	7.8	17.5	7,848	7.5	16.7	7,517	7.1	15.6
West	2,608	4.1	13.9	2,764	4.3	14.3	2,739	4.3	13.7	2,794	4.3	13.6	2,647	4.0	12.6
U.S. dependent areas	409	12.4	23.7	419	12.9	24.3	410	12.8	24.1	370	11.9	22.0	352	11.3	20.9
Total^j	16,260	6.0	16.6	16,806	6.1	16.7	16,766	6.1	16.3	16,546	6.0	15.7	15,815	5.7	14.7

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
^gData presented based on sex at birth and include transgender persons.
^hHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
^jIncludes persons of unknown race/ethnicity.

Table 7c. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2015
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	278	6.8	6.7	22.5	21.3
Alaska	12	2.0	2.1	18.2	17.5
Arizona	214	3.8	3.7	14.3	12.6
Arkansas	111	4.5	4.6	21.2	19.4
California	1,703	5.3	5.1	13.9	11.9
Colorado	123	2.7	2.7	11.0	8.2
Connecticut	183	6.0	5.2	17.7	13.9
Delaware	70	8.8	7.8	22.2	16.8
District of Columbia	255	43.8	47.5	17.7	15.4
Florida	1,977	11.4	10.6	18.6	16.2
Georgia	853	10.2	10.0	17.1	16.7
Hawaii	32	2.7	2.4	12.9	9.5
Idaho	14	1.0	1.1	13.7	10.3
Illinois	548	5.1	4.8	15.9	14.4
Indiana	179	3.3	3.2	16.9	17.3
Iowa	36	1.4	1.2	14.8	13.8
Kansas^b	51	2.1	2.0	17.9	16.9
Kentucky	127	3.4	3.4	19.0	17.5
Louisiana	419	10.9	10.9	21.5	20.9
Maine	19	1.7	1.4	13.2	8.2
Maryland	546	10.9	10.0	16.6	13.8
Massachusetts^b	300	5.2	4.7	15.1	11.8
Michigan	301	3.6	3.3	20.5	19.7
Minnesota	99	2.2	2.0	12.8	13.2
Mississippi^b	212	8.6	8.6	23.0	22.9
Missouri	172	3.4	3.3	14.5	13.8
Montana	13	1.5	1.4	22.5	19.7
Nebraska	28	1.8	1.9	13.9	13.4
Nevada^b	128	5.4	5.2	15.0	14.3
New Hampshire	29	2.5	2.2	24.9	19.3
New Jersey	638	8.5	7.7	18.3	14.9
New Mexico	75	4.3	4.3	23.0	20.3
New York	1,814	10.9	9.9	14.5	11.6
North Carolina	561	6.7	6.3	19.0	16.7
North Dakota^b	8	1.3	1.6	23.9	25.4
Ohio	308	3.2	3.0	15.0	13.6
Oklahoma	140	4.4	4.4	24.2	22.1
Oregon	111	3.3	3.1	16.7	13.3
Pennsylvania	597	5.5	5.0	17.6	14.5
Rhode Island	27	3.0	2.6	11.5	10.0
South Carolina	296	7.2	6.9	18.4	17.0
South Dakota	7	1.0	0.9	13.2	13.4
Tennessee	341	6.2	6.2	20.5	19.1
Texas	1,313	5.9	6.0	15.8	15.3
Utah	31	1.3	1.5	11.7	9.8
Vermont^b	5	0.9	0.7	7.8	5.3
Virginia	280	4.0	3.8	13.1	11.1
Washington	148	2.5	2.3	11.9	10.9
West Virginia	31	2.0	1.7	18.0	16.0
Wisconsin	84	1.7	1.6	14.3	12.6
Wyoming	4	0.8	0.8	13.9	11.0
Subtotal	15,851	5.9	5.6	16.4	14.4
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	2	1.6	1.8	23.0	14.0
Northern Mariana Islands	1	2.5	3.7	90.9	33.3
Puerto Rico	397	13.3	13.0	23.9	19.2
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	9	10.2	9.8	16.1	11.3
Subtotal	409	12.4	12.1	23.7	19.0
Total	16,260	6.0	5.7	16.6	14.5

Table 7c. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2016
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	258	6.3	6.0	20.2	19.3
Alaska	12	2.0	1.9	17.2	16.3
Arizona	244	4.2	4.1	15.7	13.5
Arkansas	98	3.9	3.9	17.9	16.1
California	1,776	5.4	5.2	14.0	11.8
Colorado	127	2.7	2.7	10.6	8.4
Connecticut	199	6.5	5.7	19.3	13.8
Delaware	56	7.0	6.1	17.6	16.6
District of Columbia	243	41.2	44.7	16.7	14.0
Florida	2,120	12.0	10.9	19.5	16.8
Georgia	848	10.0	9.7	16.4	15.7
Hawaii	39	3.2	3.0	15.8	11.3
Idaho	12	0.9	0.8	11.1	10.2
Illinois	530	4.9	4.7	15.1	13.8
Indiana	200	3.6	3.6	18.3	16.9
Iowa	33	1.3	1.2	12.8	11.0
Kansas^b	50	2.1	2.1	16.9	14.5
Kentucky	122	3.3	3.2	17.6	15.7
Louisiana	417	10.8	10.8	20.6	19.3
Maine	23	2.0	1.8	14.9	10.1
Maryland	651	12.9	11.8	19.9	17.0
Massachusetts^b	292	5.0	4.4	14.4	10.5
Michigan	287	3.4	3.2	18.5	17.3
Minnesota	74	1.6	1.5	9.2	9.1
Mississippi^b	209	8.5	8.2	22.3	21.5
Missouri	196	3.8	3.6	16.2	14.7
Montana	17	1.9	2.0	28.6	20.4
Nebraska	29	1.9	1.8	14.0	13.8
Nevada^b	150	6.2	5.9	16.6	15.4
New Hampshire	20	1.7	1.8	17.1	13.8
New Jersey	650	8.7	7.7	18.7	14.6
New Mexico	48	2.8	2.5	14.4	12.4
New York	1,866	11.2	10.1	14.7	11.8
North Carolina	523	6.1	5.8	17.2	15.7
North Dakota^b	5	0.8	0.9	13.4	9.0
Ohio	354	3.6	3.5	16.5	14.8
Oklahoma	118	3.7	3.5	19.9	18.2
Oregon	106	3.1	2.9	15.6	13.0
Pennsylvania	611	5.6	5.1	17.0	14.3
Rhode Island	39	4.3	3.7	16.0	11.8
South Carolina	342	8.2	7.6	20.7	18.3
South Dakota	11	1.6	1.5	20.1	19.4
Tennessee	330	5.9	5.6	20.0	19.0
Texas	1,360	6.0	6.1	15.8	15.5
Utah	49	2.1	2.3	17.9	17.1
Vermont^b	11	2.0	1.5	16.6	10.6
Virginia	319	4.5	4.2	14.6	12.7
Washington	179	2.9	2.7	13.9	12.9
West Virginia	41	2.6	2.4	23.0	21.5
Wisconsin	88	1.8	1.7	14.7	12.0
Wyoming	5	1.0	1.1	16.0	12.1
Subtotal	16,387	6.1	5.7	16.6	14.4
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	3	2.4	2.9	32.6	32.2
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	405	13.8	13.0	24.4	19.7
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	11	12.5	10.2	19.7	48.2
Subtotal	419	12.9	12.2	24.3	20.2
Total	16,806	6.1	5.8	16.7	14.5

Table 7c. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2017
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	262	6.4	6.3	19.7	18.1
Alaska	7	1.2	1.2	9.7	8.5
Arizona	248	4.2	4.0	15.4	13.6
Arkansas	106	4.2	4.1	18.7	16.9
California	1,725	5.3	5.0	13.3	11.1
Colorado	132	2.8	2.7	10.7	8.4
Connecticut	199	6.5	5.4	18.9	15.1
Delaware	67	8.3	7.0	20.1	13.8
District of Columbia	237	39.7	41.9	16.4	13.4
Florida	2,043	11.4	10.1	18.4	14.9
Georgia	842	9.8	9.4	15.7	14.8
Hawaii	37	3.1	2.9	15.0	15.4
Idaho	20	1.4	1.4	17.5	13.7
Illinois	498	4.6	4.3	14.0	12.8
Indiana	214	3.9	3.7	19.0	17.3
Iowa	44	1.7	1.7	16.3	13.2
Kansas^b	47	2.0	1.9	15.5	14.4
Kentucky	139	3.7	3.5	19.3	16.5
Louisiana	411	10.6	10.5	19.9	18.6
Maine	35	3.0	2.5	21.9	15.6
Maryland	600	11.9	10.8	18.1	14.8
Massachusetts^b	308	5.2	4.6	14.9	11.7
Michigan	276	3.3	3.1	17.3	15.8
Minnesota	91	2.0	1.9	10.9	9.3
Mississippi^b	220	8.9	8.8	23.1	21.3
Missouri	214	4.2	4.1	17.2	14.7
Montana	15	1.7	1.7	23.7	21.0
Nebraska	33	2.1	2.0	15.4	14.5
Nevada^b	175	7.1	6.6	18.0	16.3
New Hampshire	21	1.8	1.6	17.5	13.8
New Jersey	644	8.6	7.5	18.3	13.8
New Mexico	62	3.6	3.3	17.9	13.4
New York	1,796	10.8	9.6	14.1	10.7
North Carolina	554	6.4	5.9	17.7	15.4
North Dakota^b	3	0.5	0.4	7.3	8.9
Ohio	380	3.9	3.7	17.1	15.6
Oklahoma	108	3.3	3.4	17.7	16.8
Oregon	116	3.3	3.0	16.6	12.5
Pennsylvania	650	6.0	5.4	18.1	14.6
Rhode Island	34	3.7	3.3	13.2	9.8
South Carolina	339	8.0	7.3	20.0	17.5
South Dakota	9	1.3	1.3	15.4	12.4
Tennessee	335	5.9	5.7	19.8	18.5
Texas	1,418	6.2	6.2	15.8	15.1
Utah	22	0.9	1.0	8.0	8.4
Vermont^b	12	2.2	1.9	17.1	11.4
Virginia	296	4.2	3.8	13.1	10.7
Washington	175	2.8	2.6	13.1	10.4
West Virginia	31	2.0	1.8	17.0	13.8
Wisconsin	101	2.1	1.9	16.2	12.8
Wyoming	5	1.0	0.9	15.2	25.3
Subtotal	16,356	6.0	5.6	16.1	13.7
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	0	0.0	0.0	0.0	0.0
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	404	14.0	13.1	24.7	19.3
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	6	6.8	6.5	11.1	8.4
Subtotal	410	12.8	12.0	24.1	18.8
Total	16,766	6.1	5.7	16.3	13.8

Table 7c. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2018
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	234	5.7	5.4	17.1	15.2
Alaska	9	1.5	1.4	12.6	9.3
Arizona	249	4.2	3.9	14.9	12.5
Arkansas	84	3.4	3.4	14.5	12.9
California	1,734	5.3	4.9	13.1	10.6
Colorado	142	3.0	2.9	11.1	8.4
Connecticut	183	6.0	5.0	17.2	11.7
Delaware	68	8.3	7.2	20.2	14.9
District of Columbia	200	33.3	36.4	14.0	11.4
Florida	1,934	10.6	9.4	17.1	13.6
Georgia	849	9.7	9.4	15.3	14.0
Hawaii	36	3.0	2.6	15.0	10.2
Idaho	15	1.0	1.1	12.6	8.7
Illinois	551	5.2	4.8	15.2	13.4
Indiana	197	3.5	3.4	17.0	15.0
Iowa	51	1.9	1.8	18.1	14.4
Kansas^b	48	2.0	1.9	15.4	14.0
Kentucky	136	3.6	3.5	18.2	15.8
Louisiana	427	11.1	10.8	20.1	18.1
Maine	20	1.7	1.5	12.3	8.3
Maryland	631	12.4	11.0	18.7	15.1
Massachusetts^b	304	5.1	4.5	14.5	10.8
Michigan	313	3.7	3.3	19.2	17.2
Minnesota	85	1.8	1.7	9.9	7.7
Mississippi^b	229	9.2	9.2	23.5	21.0
Missouri	238	4.6	4.3	18.6	15.8
Montana	13	1.5	1.4	19.9	16.2
Nebraska	31	2.0	1.8	14.2	12.8
Nevada^b	146	5.8	5.4	14.2	12.3
New Hampshire	18	1.5	1.4	14.2	15.3
New Jersey	640	8.5	7.4	18.1	13.7
New Mexico	74	4.2	4.1	20.2	15.9
New York	1,743	10.5	9.3	13.6	10.1
North Carolina	532	6.1	5.5	16.5	13.8
North Dakota^b	8	1.3	1.3	17.5	24.2
Ohio	373	3.8	3.6	16.4	14.1
Oklahoma	116	3.6	3.4	18.5	17.0
Oregon	105	3.0	2.7	14.7	12.5
Pennsylvania	574	5.3	4.7	15.7	12.5
Rhode Island	41	4.5	4.0	15.6	10.9
South Carolina	319	7.4	7.0	18.3	15.5
South Dakota	13	1.8	1.9	20.8	16.2
Tennessee	360	6.3	6.0	20.5	18.3
Texas	1,374	5.9	5.9	14.8	13.9
Utah	46	1.9	2.1	15.4	13.6
Vermont^b	11	2.0	1.5	15.3	9.3
Virginia	308	4.3	4.0	13.3	11.3
Washington	218	3.5	3.2	15.8	12.2
West Virginia	47	3.0	2.8	24.3	21.0
Wisconsin	92	1.9	1.7	14.4	12.2
Wyoming	7	1.5	1.4	19.8	15.6
Subtotal	16,176	5.9	5.5	15.6	12.9
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	4	3.1	3.7	38.1	37.7
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	362	12.9	11.8	22.4	18.8
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	4	4.5	3.1	7.3	4.8
Subtotal	370	11.9	10.9	22.0	18.5
Total	16,546	6.0	5.5	15.7	13.0

Table 7c. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2019
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	268	6.5	6.1	19.0	16.6
Alaska	11	1.8	1.9	15.0	11.8
Arizona	228	3.7	3.6	13.0	11.1
Arkansas	97	3.9	3.7	16.1	15.3
California	1,747	5.3	4.9	13.0	10.7
Colorado	121	2.5	2.4	9.2	7.4
Connecticut	202	6.6	5.4	18.7	12.6
Delaware	67	8.1	7.2	19.4	14.7
District of Columbia	184	30.5	32.8	12.9	9.9
Florida	1,933	10.5	9.0	16.8	13.3
Georgia	806	9.1	8.7	14.1	12.8
Hawaii	43	3.6	3.0	17.7	12.2
Idaho	11	0.7	0.7	8.8	6.3
Illinois	530	5.0	4.5	14.6	12.6
Indiana	141	2.5	2.4	12.0	10.1
Iowa	58	2.2	1.9	19.7	16.1
Kansas^b	28	1.2	1.1	8.7	8.1
Kentucky	106	2.8	2.6	13.7	12.2
Louisiana	367	9.5	9.4	16.9	15.4
Maine	39	3.3	2.9	23.1	16.2
Maryland	567	11.1	9.9	16.7	13.2
Massachusetts^b	167	2.8	2.5	7.9	6.4
Michigan	273	3.2	2.9	16.2	14.3
Minnesota	82	1.7	1.6	9.2	8.2
Mississippi^b	129	5.2	5.0	13.0	11.6
Missouri	227	4.4	4.1	17.4	16.3
Montana	8	0.9	1.0	11.8	8.8
Nebraska	31	1.9	1.9	13.7	10.9
Nevada^b	87	3.4	3.3	8.0	7.9
New Hampshire	15	1.3	1.2	11.4	7.3
New Jersey	615	8.2	6.9	17.2	12.3
New Mexico	52	3.0	2.7	13.7	10.8
New York	1,787	10.8	9.3	13.9	10.2
North Carolina	474	5.4	4.9	14.2	11.6
North Dakota^b	2	0.3	0.4	4.0	2.8
Ohio	384	3.9	3.7	16.3	14.5
Oklahoma	131	4.0	3.8	20.2	18.1
Oregon	122	3.4	3.1	16.5	12.8
Pennsylvania	577	5.3	4.6	15.6	12.2
Rhode Island	40	4.4	3.5	14.9	10.9
South Carolina	299	6.9	6.1	16.7	14.2
South Dakota	9	1.2	1.4	13.7	9.9
Tennessee	307	5.3	5.1	17.1	14.6
Texas	1,434	6.1	6.0	14.8	13.6
Utah	35	1.4	1.4	11.2	9.3
Vermont^b	8	1.5	1.4	11.0	7.4
Virginia	303	4.2	3.8	12.6	10.2
Washington	177	2.8	2.5	12.5	10.2
West Virginia	45	2.9	2.7	22.2	17.2
Wisconsin	84	1.7	1.5	12.8	10.2
Wyoming	5	1.0	0.8	14.3	10.6
Subtotal	15,463	5.6	5.1	14.6	12.0
U.S. dependent area
American Samoa	2	5.3	6.4	666.7	365.5
Guam	4	3.1	3.1	36.0	26.3
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	346	12.3	11.7	21.4	17.1
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	0	0.0	0.0	0.0	0.0
Subtotal	352	11.3	10.8	20.9	16.8
Total	15,815	5.7	5.2	14.7	12.1

Abbreviations: PWDH, persons with diagnosed HIV infection; pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
^bData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 7d. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2015–2019—United States
	2015			2016			2017			2018			2019
	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a
Gender
Male	9,607	–	24.3	9,717	–	24.3	9,663	–	23.9	9,418	–	23.1	9,023	–	22.0
Female	3,112	–	25.0	3,165	–	25.1	3,089	–	24.3	3,112	–	24.3	2,775	–	21.5
Transgender male-to-female^b	88	–	19.8	100	–	21.8	74	–	15.7	90	–	18.4	97	–	19.3
Transgender female-to-male^b	2	–	13.6	1	–	6.6	3	–	19.0	1	–	6.1	3	–	17.5
Additional gender identity^c	1	–	18.2	0	–	0.0	1	–	15.4	1	–	14.7	1	–	14.9
Age at death (yr)
13–24	115	0.2	11.0	95	0.2	10.2	88	0.2	10.6	77	0.2	10.5	69	0.1	10.8
25–34	755	1.7	15.1	774	1.7	15.5	709	1.6	14.2	718	1.6	14.5	686	1.5	13.9
35–44	1,637	4.0	16.2	1,539	3.8	16.1	1,402	3.4	15.3	1,334	3.2	15.0	1,223	2.9	14.0
45–54	4,128	9.6	21.1	3,825	9.0	19.9	3,615	8.6	19.5	3,368	8.1	19.1	2,750	6.7	16.6
≥55	6,175	7.0	36.8	6,750	7.5	36.6	7,016	7.6	34.9	7,125	7.5	32.7	7,171	7.4	30.5
Race/ethnicity
American Indian/Alaska Native	50	2.6	36.3	37	1.9	26.1	36	1.8	24.7	34	1.7	22.9	41	2.1	27.1
Asian^d	64	0.4	10.9	82	0.5	13.4	67	0.4	10.5	64	0.4	9.6	72	0.4	10.5
Black/African American	5,694	17.4	27.0	5,737	17.4	26.8	5,642	16.9	26.1	5,445	16.2	24.9	5,099	15.0	23.2
Hispanic/Latino^e	2,135	5.0	17.4	2,171	4.9	17.3	2,232	5.0	17.5	2,295	5.0	17.7	2,182	4.6	16.6
Native Hawaiian/other Pacific Islander	5	1.1	13.2	10	2.2	25.7	8	1.7	20.0	9	1.9	21.8	12	2.4	28.2
White	3,972	2.3	25.7	4,086	2.4	26.4	3,950	2.3	25.5	3,876	2.3	25.0	3,637	2.1	23.5
Multiracial	890	21.0	30.5	860	19.6	29.5	895	19.7	30.7	899	19.1	31.1	855	17.6	29.8
Transmission category^f
Male adult or adolescent^g
Male-to-male sexual contact	5,249	–	19.9	5,373	–	20.0	5,433	–	19.9	5,245	–	19.0	5,180	–	18.5
Injection drug use	1,895	–	38.5	1,844	–	38.3	1,759	–	37.2	1,731	–	37.2	1,551	–	34.0
Male-to-male sexual contact and injection drug use	1,190	–	32.6	1,161	–	32.1	1,132	–	31.5	1,203	–	33.9	1,052	–	30.0
Heterosexual contact^h	1,273	–	27.1	1,355	–	28.3	1,331	–	27.5	1,236	–	25.3	1,254	–	25.4
Otherⁱ	89	–	19.6	84	–	18.6	84	–	18.6	92	–	20.2	83	–	18.3
Subtotal	9,696	7.4	24.2	9,817	7.4	24.2	9,738	7.3	23.8	9,508	7.1	23.1	9,121	6.8	22.0
Female adult or adolescent^g
Injection drug use	1,104	–	35.1	1,116	–	35.9	1,094	–	35.5	1,043	–	34.3	944	–	31.3
Heterosexual contact^h	1,942	–	21.7	1,982	–	21.8	1,935	–	20.9	2,019	–	21.5	1,784	–	18.8
Otherⁱ	68	–	17.7	67	–	17.1	63	–	15.9	52	–	12.8	50	–	12.3
Subtotal	3,114	2.3	24.9	3,166	2.3	25.1	3,092	2.2	24.3	3,114	2.2	24.3	2,778	2.0	21.5
Region of residence
Northeast	2,921	6.1	21.9	2,924	6.1	21.8	2,880	6.0	21.6	2,757	5.8	20.7	2,718	5.7	20.5
Midwest	1,438	2.5	24.6	1,446	2.5	24.2	1,444	2.5	23.9	1,526	2.7	24.9	1,367	2.4	22.1
South	6,296	6.3	27.4	6,373	6.3	27.5	6,268	6.1	26.6	6,070	5.8	25.4	5,740	5.5	23.7
West	2,155	3.4	20.8	2,240	3.5	21.3	2,238	3.5	21.0	2,269	3.5	21.2	2,074	3.2	19.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,122	4.5	19.2	8,311	4.5	19.4	8,304	4.5	19.1	8,047	4.3	18.4	8,404	4.5	19.1
Metropolitan areas (pop. 50,000–499,999)	1,218	2.6	24.1	1,096	2.3	21.4	1,192	2.5	22.7	1,177	2.5	22.1	1,212	2.5	22.0
Nonmetropolitan areas (pop. <50,000)	710	1.8	24.6	692	1.8	23.7	756	1.9	25.2	662	1.7	21.9	722	1.9	23.4
Total^j	12,810	4.8	24.4	12,983	4.8	24.4	12,830	4.7	23.9	12,622	4.6	23.4	11,899	4.3	21.9

Abbreviations: pop, population; PWA, diagnosed HIV infection ever classified as stage 3(AIDS); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
^gData presented based on sex at birth and include transgender persons.
^hHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
^jIncludes persons of unknown race/ethnicity.

Table 7e. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2015–2019—United States and 6 dependent areas
	2015			2016			2017			2018			2019
	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a
Gender
Male	9,835	–	24.4	9,947	–	24.4	9,868	–	24.0	9,616	–	23.3	9,208	–	22.1
Female	3,189	–	25.0	3,228	–	25.1	3,162	–	24.4	3,159	–	24.1	2,831	–	21.5
Transgender male-to-female^b	88	–	19.7	100	–	21.7	76	–	16.1	91	–	18.6	99	–	19.7
Transgender female-to-male^b	2	–	13.6	1	–	6.6	3	–	19.0	1	–	6.1	3	–	17.5
Additional gender identity^c	1	–	18.2	0	–	0.0	1	–	15.4	1	–	14.7	1	–	14.9
Age at death (yr)
13-24	117	0.2	11.1	100	0.2	10.6	90	0.2	10.7	81	0.2	10.9	70	0.1	10.8
25-34	775	1.7	15.3	782	1.7	15.5	723	1.6	14.3	731	1.6	14.6	696	1.5	14.0
35-44	1,675	4.1	16.3	1,581	3.9	16.3	1,437	3.5	15.4	1,368	3.3	15.1	1,250	3.0	14.1
45-54	4,242	9.7	21.3	3,915	9.1	20.0	3,702	8.7	19.6	3,427	8.1	19.1	2,832	6.8	16.8
≥55	6,306	7.0	36.8	6,898	7.5	36.7	7,158	7.6	34.9	7,261	7.6	32.7	7,294	7.5	30.4
Race/ethnicity
American Indian/Alaska Native	50	–	36.3	37	–	26.1	36	–	24.7	34	–	22.9	41	–	27.1
Asian^d	64	–	10.9	82	–	13.4	67	–	10.5	64	–	9.6	72	–	10.5
Black/African American	5,698	–	27.0	5,746	–	26.8	5,645	–	26.1	5,445	–	24.9	5,099	–	23.1
Hispanic/Latino^e	2,434	–	18.4	2,451	–	18.2	2,509	–	18.4	2,537	–	18.3	2,419	–	17.2
Native Hawaiian/other Pacific Islander	6	–	15.3	12	–	29.6	8	–	19.0	11	–	25.3	15	–	33.6
White	3,972	–	25.7	4,087	–	26.4	3,950	–	25.5	3,877	–	25.0	3,638	–	23.5
Multiracial	891	–	30.5	861	–	29.5	895	–	30.7	900	–	31.1	857	–	29.9
Transmission category^f
Male adult or adolescent^g
Male-to-male sexual contact	5,310	–	20.0	5,428	–	20.1	5,483	–	20.0	5,297	–	19.0	5,236	–	18.5
Injection drug use	1,993	–	38.7	1,937	–	38.3	1,848	–	37.3	1,814	–	37.3	1,631	–	34.2
Male-to-male sexual contact and injection drug use	1,216	–	32.8	1,190	–	32.4	1,151	–	31.6	1,220	–	33.9	1,068	–	30.0
Heterosexual contact^h	1,315	–	27.2	1,404	–	28.5	1,378	–	27.7	1,277	–	25.4	1,288	–	25.4
Otherⁱ	90	–	19.4	88	–	19.1	85	–	18.4	98	–	21.1	85	–	18.4
Subtotal	9,924	7.5	24.4	10,047	7.5	24.4	9,945	7.4	24.0	9,707	7.2	23.2	9,308	6.8	22.1
Female adult or adolescent^g
Injection drug use	1,119	–	34.8	1,141	–	35.9	1,114	–	35.5	1,065	–	34.3	964	–	31.4
Heterosexual contact^h	2,003	–	21.9	2,019	–	21.7	1,987	–	21.0	2,043	–	21.3	1,819	–	18.8
Otherⁱ	69	–	17.6	69	–	17.2	64	–	15.8	54	–	13.0	51	–	12.4
Subtotal	3,191	2.3	25.0	3,229	2.3	25.1	3,165	2.2	24.3	3,161	2.2	24.1	2,834	2.0	21.5
Region of residence
Northeast	2,921	6.1	21.9	2,924	6.1	21.8	2,880	6.0	21.6	2,757	5.8	20.7	2,718	5.7	20.5
Midwest	1,438	2.5	24.6	1,446	2.5	24.2	1,444	2.5	23.9	1,526	2.7	24.9	1,367	2.4	22.1
South	6,296	6.3	27.4	6,373	6.3	27.5	6,268	6.1	26.6	6,070	5.8	25.4	5,740	5.5	23.7
West	2,155	3.4	20.8	2,240	3.5	21.3	2,238	3.5	21.0	2,269	3.5	21.2	2,074	3.2	19.2
U.S. dependent areas	305	9.3	32.3	293	9.0	31.3	280	8.8	30.5	246	7.9	27.2	243	7.8	27.0
Total^j	13,115	4.8	24.5	13,276	4.9	24.6	13,110	4.8	24.0	12,868	4.6	23.4	12,142	4.3	21.9

Abbreviations: pop, population; PWA, diagnosed HIV infection ever classified as stage 3(AIDS); CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
^b“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
^gData presented based on sex at birth and include transgender persons.
^hHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
^jIncludes persons of unknown race/ethnicity.

Table 7f. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2015
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	210	5.2	5.2	37.3	33.5
Alaska	9	1.5	1.6	24.3	20.9
Arizona	174	3.1	3.0	23.2	20.7
Arkansas	85	3.4	3.5	34.3	31.9
California	1,417	4.4	4.3	20.3	16.8
Colorado	102	2.2	2.2	20.1	14.6
Connecticut	158	5.2	4.5	24.1	21.8
Delaware	57	7.2	6.4	28.9	20.0
District of Columbia	192	33.0	36.0	24.5	22.5
Florida	1,652	9.6	8.9	27.8	24.7
Georgia	671	8.0	7.9	25.6	23.2
Hawaii	27	2.3	2.1	18.4	13.1
Idaho	7	0.5	0.5	13.5	10.2
Illinois	454	4.2	4.0	25.3	21.1
Indiana	138	2.5	2.5	25.3	28.9
Iowa	29	1.1	1.0	21.1	17.5
Kansas^b	43	1.8	1.7	28.3	23.3
Kentucky	96	2.6	2.6	27.9	24.4
Louisiana	346	9.0	9.0	33.3	32.7
Maine	15	1.3	1.2	19.9	11.0
Maryland	457	9.1	8.4	25.1	19.6
Massachusetts^b	227	3.9	3.5	19.8	15.1
Michigan	243	2.9	2.6	31.0	28.3
Minnesota	71	1.6	1.5	19.1	24.6
Mississippi^b	175	7.1	7.1	38.3	35.5
Missouri	128	2.5	2.4	20.1	18.4
Montana	11	1.3	1.2	32.1	27.4
Nebraska	22	1.4	1.4	20.7	26.5
Nevada^b	104	4.4	4.2	24.3	25.0
New Hampshire	24	2.1	1.8	38.8	29.0
New Jersey	517	6.9	6.2	27.7	22.8
New Mexico	68	3.9	3.9	36.1	37.3
New York	1,487	8.9	8.1	19.9	15.9
North Carolina	409	4.9	4.6	30.0	24.3
North Dakota^b	7	1.1	1.3	40.7	38.9
Ohio	231	2.4	2.3	23.3	20.8
Oklahoma	121	3.8	3.9	41.7	39.2
Oregon	88	2.6	2.4	22.8	16.6
Pennsylvania	471	4.3	4.0	24.8	18.5
Rhode Island	19	2.1	1.7	14.0	10.6
South Carolina	237	5.8	5.6	26.7	25.3
South Dakota	6	0.9	0.7	24.3	24.4
Tennessee	252	4.6	4.6	29.8	28.3
Texas	1,085	4.9	5.0	24.5	21.8
Utah	27	1.2	1.3	18.9	13.6
Vermont^b	3	0.6	0.4	8.6	5.1
Virginia	222	3.2	3.0	21.3	17.6
Washington	120	2.0	1.9	17.2	16.7
West Virginia	29	1.8	1.6	29.4	23.1
Wisconsin	66	1.4	1.3	22.3	19.2
Wyoming	1	0.2	0.2	6.5	2.9
Subtotal	12,810	4.8	4.6	24.4	21.2
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	2	1.6	1.8	62.5	35.3
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	297	10.0	9.7	32.7	29.3
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	6	6.8	6.2	19.4	13.3
Subtotal	305	9.3	9.0	32.3	28.8
Total	13,115	4.8	4.6	24.5	21.3

Table 7f. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2016
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	192	4.7	4.5	33.5	31.7
Alaska	7	1.2	1.1	18.1	14.3
Arizona	196	3.4	3.3	25.8	20.3
Arkansas	69	2.8	2.7	27.2	21.5
California	1,463	4.5	4.3	20.7	17.7
Colorado	98	2.1	2.1	18.2	13.8
Connecticut	162	5.3	4.6	25.0	17.3
Delaware	47	5.9	5.1	23.9	27.2
District of Columbia	191	32.4	35.4	24.5	19.7
Florida	1,726	9.8	8.9	28.9	24.6
Georgia	668	7.8	7.7	25.1	22.8
Hawaii	30	2.5	2.3	20.8	14.5
Idaho	8	0.6	0.5	14.5	11.0
Illinois	412	3.8	3.7	23.0	19.7
Indiana	163	3.0	2.9	29.4	25.3
Iowa	28	1.1	1.0	19.4	15.5
Kansas^b	37	1.5	1.5	23.9	18.1
Kentucky	95	2.6	2.4	27.0	22.7
Louisiana	331	8.6	8.6	31.2	29.5
Maine	16	1.4	1.2	20.3	11.8
Maryland	517	10.3	9.4	29.1	23.6
Massachusetts^b	218	3.7	3.2	19.1	12.4
Michigan	227	2.7	2.5	27.8	23.9
Minnesota	57	1.2	1.1	15.0	14.8
Mississippi_b	164	6.6	6.5	35.3	31.0
Missouri	162	3.2	2.9	25.3	21.8
Montana	14	1.6	1.6	40.8	24.9
Nebraska	27	1.7	1.7	25.4	22.6
Nevada^b	117	4.8	4.6	26.2	26.3
New Hampshire	15	1.3	1.3	24.6	19.2
New Jersey	476	6.4	5.6	26.0	21.3
New Mexico	41	2.4	2.1	21.9	17.6
New York	1,532	9.2	8.3	20.5	16.4
North Carolina	383	4.5	4.2	27.7	25.8
North Dakota^b	4	0.6	0.7	21.4	12.6
Ohio	254	2.6	2.5	24.5	19.9
Oklahoma	91	2.8	2.7	30.9	25.7
Oregon	85	2.5	2.3	21.8	15.5
Pennsylvania	460	4.2	3.8	22.7	19.2
Rhode Island	34	3.7	3.2	24.5	14.6
South Carolina	278	6.7	6.2	30.8	25.5
South Dakota	6	0.9	0.8	23.6	22.1
Tennessee	246	4.4	4.2	29.4	25.5
Texas	1,094	4.8	4.9	24.4	22.0
Utah	38	1.6	1.8	26.3	20.4
Vermont^b	11	2.0	1.5	30.4	16.3
Virginia	248	3.5	3.3	23.4	21.4
Washington	139	2.3	2.1	19.8	17.7
West Virginia	33	2.1	1.9	32.5	26.0
Wisconsin	69	1.4	1.3	23.0	17.3
Wyoming	4	0.8	0.9	22.9	12.8
Subtotal	12,983	4.8	4.5	24.4	20.8
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	3	2.4	2.9	83.3	72.8
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	279	9.5	9.0	31.0	27.9
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	11	12.5	10.2	35.6	99.5
Subtotal	293	9.0	8.5	31.3	30.8
Total	13,276	4.9	4.6	24.6	21.0

Table 7f. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2017
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	198	4.8	4.8	33.4	28.3
Alaska	4	0.7	0.7	10.2	7.6
Arizona	195	3.3	3.1	25.1	25.6
Arkansas	80	3.2	3.1	30.5	25.7
California	1,434	4.4	4.2	20.2	17.2
Colorado	106	2.3	2.2	19.6	18.7
Connecticut	160	5.2	4.3	24.6	23.0
Delaware	58	7.2	6.0	28.3	18.0
District of Columbia	164	27.5	29.0	21.4	18.4
Florida	1,641	9.1	8.2	27.2	21.9
Georgia	658	7.6	7.4	23.9	21.6
Hawaii	31	2.6	2.5	21.6	36.0
Idaho	15	1.1	1.1	26.3	20.0
Illinois	374	3.5	3.3	20.8	18.8
Indiana	167	3.0	2.9	29.5	26.5
Iowa	31	1.2	1.2	20.5	14.2
Kansas^b	37	1.5	1.5	23.5	25.8
Kentucky	108	2.9	2.7	30.0	23.0
Louisiana	313	8.1	8.0	29.1	28.6
Maine	24	2.1	1.7	29.6	22.8
Maryland	473	9.3	8.5	26.5	19.5
Massachusetts^b	233	4.0	3.4	20.3	13.0
Michigan	226	2.7	2.5	27.5	23.3
Minnesota	69	1.5	1.4	17.8	14.4
Mississippi^b	174	7.0	7.0	36.8	31.8
Missouri	155	3.0	2.9	24.1	18.6
Montana	13	1.5	1.4	37.4	37.6
Nebraska	23	1.5	1.4	21.6	17.3
Nevada^b	137	5.5	5.1	29.0	29.1
New Hampshire	15	1.3	1.1	24.6	19.2
New Jersey	474	6.3	5.5	25.8	18.6
New Mexico	49	2.8	2.5	25.7	16.6
New York	1,467	8.8	7.8	19.8	14.9
North Carolina	393	4.6	4.2	27.7	23.7
North Dakota^b	3	0.5	0.4	15.4	14.6
Ohio	279	2.8	2.7	26.3	22.6
Oklahoma	82	2.5	2.6	27.4	25.1
Oregon	86	2.4	2.3	21.7	14.2
Pennsylvania	474	4.3	3.9	24.0	18.8
Rhode Island	28	3.1	2.6	19.4	14.4
South Carolina	264	6.2	5.7	28.7	23.2
South Dakota	3	0.4	0.5	11.5	8.2
Tennessee	259	4.6	4.4	30.5	27.4
Texas	1,150	5.0	5.0	25.1	23.5
Utah	19	0.8	0.8	13.5	9.4
Vermont^b	5	0.9	0.8	13.4	11.1
Virginia	228	3.2	2.9	20.9	16.7
Washington	145	2.3	2.2	20.2	14.6
West Virginia	25	1.6	1.5	24.7	18.9
Wisconsin	77	1.6	1.5	25.0	18.0
Wyoming	4	0.8	0.7	22.5	51.9
Subtotal	12,830	4.7	4.4	23.9	20.0
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	0	0.0	0.0	0.0	0.0
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	276	9.6	8.9	31.3	28.7
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	4	4.5	4.0	13.6	10.0
Subtotal	280	8.8	8.2	30.5	27.9
Total	13,110	4.8	4.4	24.0	20.1

Table 7f. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2018
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	164	4.0	3.8	27.1	23.9
Alaska	8	1.3	1.2	20.8	13.4
Arizona	197	3.3	3.1	24.9	22.4
Arkansas	62	2.5	2.5	23.5	20.6
California	1,413	4.3	4.0	19.8	17.2
Colorado	116	2.4	2.4	20.9	15.1
Connecticut	147	4.8	4.0	22.6	14.0
Delaware	54	6.6	5.6	26.5	18.1
District of Columbia	154	25.6	27.9	20.1	18.9
Florida	1,531	8.4	7.4	25.3	20.0
Georgia	653	7.5	7.2	23.2	19.9
Hawaii	31	2.6	2.2	22.3	15.2
Idaho	13	0.9	0.9	22.3	14.8
Illinois	424	4.0	3.6	23.3	19.8
Indiana	147	2.6	2.6	25.4	23.8
Iowa	35	1.3	1.2	22.8	15.1
Kansas^b	38	1.6	1.5	23.6	25.8
Kentucky	102	2.7	2.6	28.2	24.9
Louisiana	330	8.5	8.3	30.4	26.0
Maine	16	1.4	1.3	19.3	13.9
Maryland	499	9.8	8.7	27.8	21.6
Massachusetts^b	231	3.9	3.4	20.2	13.3
Michigan	242	2.9	2.5	29.2	24.8
Minnesota	65	1.4	1.3	16.5	11.8
Mississippi^b	188	7.6	7.6	39.1	34.3
Missouri	179	3.5	3.2	27.4	23.5
Montana	10	1.1	1.0	28.2	21.1
Nebraska	24	1.5	1.4	22.4	17.3
Nevada^b	125	4.9	4.6	25.4	22.8
New Hampshire	15	1.3	1.2	24.0	14.2
New Jersey	473	6.3	5.4	25.9	22.0
New Mexico	52	3.0	3.0	26.3	23.4
New York	1,412	8.5	7.5	19.2	13.3
North Carolina	361	4.1	3.8	24.9	19.1
North Dakota^b	6	1.0	0.9	29.0	25.0
Ohio	289	2.9	2.8	26.7	23.1
Oklahoma	85	2.6	2.5	27.8	32.2
Oregon	88	2.5	2.2	22.0	15.5
Pennsylvania	423	3.9	3.4	21.3	14.8
Rhode Island	32	3.5	3.1	22.0	13.7
South Carolina	242	5.6	5.3	26.0	19.7
South Dakota	11	1.5	1.6	38.3	33.1
Tennessee	276	4.9	4.6	31.6	27.2
Texas	1,106	4.7	4.8	23.7	22.7
Utah	36	1.5	1.6	24.5	38.5
Vermont^b	8	1.5	1.1	20.7	10.9
Virginia	225	3.1	2.9	20.2	17.9
Washington	173	2.7	2.5	23.7	16.8
West Virginia	38	2.5	2.2	36.4	35.8
Wisconsin	66	1.3	1.2	21.5	17.5
Wyoming	7	1.5	1.4	39.3	26.3
Subtotal	12,622	4.6	4.3	23.4	19.3
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0
Guam	3	2.4	3.0	68.2	85.3
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	241	8.6	7.9	27.8	32.2
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	2	2.3	1.5	6.7	3.7
Subtotal	246	7.9	7.3	27.2	31.4
Total	12,868	4.6	4.3	23.4	19.4

Table 7f. Deaths of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2015–2019—United States and 6 dependent areas
	2019
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	166	4.0	3.9	26.7	21.3
Alaska	8	1.3	1.3	21.2	12.2
Arizona	168	2.7	2.7	20.7	15.7
Arkansas	70	2.8	2.7	25.6	28.4
California	1,371	4.1	3.9	19.2	19.2
Colorado	93	1.9	1.8	16.5	12.0
Connecticut	167	5.5	4.5	25.6	17.5
Delaware	53	6.4	5.8	25.7	21.3
District of Columbia	132	21.9	23.8	17.4	11.9
Florida	1,510	8.2	7.0	24.7	20.2
Georgia	626	7.1	6.7	21.9	18.7
Hawaii	38	3.2	2.6	27.4	19.2
Idaho	11	0.7	0.7	17.8	11.2
Illinois	399	3.7	3.4	22.2	17.8
Indiana	110	2.0	1.9	19.0	13.7
Iowa	42	1.6	1.4	27.2	19.6
Kansas^b	24	1.0	1.0	14.9	19.7
Kentucky	80	2.1	2.0	21.7	17.2
Louisiana	290	7.5	7.4	26.4	25.6
Maine	32	2.7	2.3	37.8	29.0
Maryland	429	8.4	7.5	24.0	17.9
Massachusetts^b	129	2.2	1.9	11.3	9.1
Michigan	214	2.5	2.2	25.4	22.0
Minnesota	57	1.2	1.1	14.2	14.2
Mississippi^b	85	3.4	3.3	17.6	13.8
Missouri	164	3.2	2.9	24.9	25.3
Montana	7	0.8	0.9	20.1	15.0
Nebraska	16	1.0	1.0	14.7	9.7
Nevada^b	67	2.6	2.5	13.3	13.8
New Hampshire	11	0.9	0.9	17.4	11.2
New Jersey	465	6.2	5.2	25.5	19.2
New Mexico	34	1.9	1.8	17.0	13.1
New York	1,443	8.7	7.5	19.8	14.3
North Carolina	333	3.8	3.5	22.3	18.1
North Dakota^b	2	0.3	0.4	9.0	6.1
Ohio	268	2.7	2.5	24.2	22.8
Oklahoma	112	3.4	3.3	36.1	29.6
Oregon	99	2.8	2.5	24.4	19.0
Pennsylvania	430	3.9	3.4	21.4	15.2
Rhode Island	34	3.7	2.9	23.3	15.2
South Carolina	224	5.1	4.6	23.7	17.7
South Dakota	8	1.1	1.2	26.4	16.8
Tennessee	242	4.2	4.0	27.4	21.0
Texas	1,122	4.7	4.7	23.5	20.7
Utah	29	1.1	1.2	19.5	14.8
Vermont^b	7	1.3	1.3	18.4	13.5
Virginia	234	3.2	2.9	20.5	17.8
Washington	145	2.3	2.0	19.7	18.7
West Virginia	32	2.1	1.8	30.5	22.2
Wisconsin	63	1.3	1.1	19.9	14.4
Wyoming	4	0.8	0.6	22.3	13.1
Subtotal	11,899	4.3	3.9	21.9	18.1
U.S. dependent area
American Samoa	2	5.3	6.4	1000.0	365.5
Guam	4	3.1	3.1	90.9	74.5
Northern Mariana Islands	0	0.0	0.0	0.0	0.0
Puerto Rico	237	8.4	7.8	27.4	23.9
Republic of Palau	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	0	0.0	0.0	0.0	0.0
Subtotal	243	7.8	7.2	27.0	23.7
Total	12,142	4.3	4.0	21.9	18.1

Abbreviations: PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for the year 2019 are preliminary and based on death data received by CDC as of December 2020. Trends through 2019 should be interpreted with caution.

^aDenominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
^bData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 8a. Persons surviving >3 years after a diagnosis of HIV infection during 2011–2016, by year of diagnosis and selected characteristics—United States
	Proportion survived >3 years
	No.	2011	2012	2013	2014	2015	2016
Gender
Male	188,262	0.94	0.94	0.94	0.95	0.95	0.95
Female	46,332	0.93	0.93	0.92	0.94	0.94	0.94
Transgender male-to-female^a	3,358	0.98	0.99	0.98	0.98	0.97	0.96
Transgender female-to-male^a	121	*	*	*	*	*	*
Additional gender identity^b	47	*	*	*	*	*	*
Age at diagnosis (yr)
13–24	53,267	0.99	0.99	0.99	0.99	0.99	0.99
25–34	73,620	0.97	0.97	0.97	0.97	0.98	0.98
35–44	48,144	0.94	0.95	0.94	0.95	0.95	0.95
45–54	40,458	0.89	0.90	0.90	0.91	0.92	0.91
≥55	22,631	0.80	0.81	0.80	0.82	0.82	0.83
Race/ethnicity
American Indian/Alaska Native	985	0.91	0.91	0.90	0.94	0.95	0.95
Asian	4,795	0.96	0.97	0.96	0.97	0.97	0.96
Black/African American	100,904	0.93	0.94	0.94	0.94	0.95	0.95
Hispanic/Latino^c	59,436	0.95	0.95	0.95	0.96	0.96	0.96
Native Hawaiian/other Pacific Islander	282	*	*	*	*	*	*
White	61,308	0.92	0.94	0.93	0.94	0.94	0.93
Multiracial	10,410	0.96	0.95	0.95	0.95	0.94	0.94
Transmission category^d
Male-to-male sexual contact	154,052	0.95	0.96	0.95	0.96	0.96	0.96
Injection drug use
Male	7,919	0.85	0.86	0.85	0.86	0.88	0.87
Female	6,412	0.89	0.89	0.88	0.89	0.91	0.89
Male-to-male sexual contact and injection drug use	9,206	0.95	0.94	0.94	0.95	0.95	0.94
Heterosexual contact^e
Male	20,278	0.89	0.90	0.89	0.91	0.91	0.92
Female	39,843	0.93	0.94	0.93	0.94	0.95	0.95
Region of residence
Northeast	40,880	0.94	0.94	0.94	0.95	0.95	0.95
Midwest	31,265	0.95	0.95	0.94	0.95	0.95	0.95
South	120,894	0.93	0.94	0.94	0.94	0.95	0.95
West	45,081	0.94	0.95	0.94	0.95	0.95	0.95
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	195,824	0.94	0.95	0.94	0.95	0.95	0.95
Metropolitan areas (pop. 50,000–499,999)	26,797	0.92	0.93	0.92	0.93	0.94	0.94
Nonmetropolitan areas (pop. <50,000)	14,006	0.91	0.91	0.91	0.92	0.92	0.93
Total^f	238,120	0.94	0.94	0.94	0.95	0.95	0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cHispanic/Latino persons can be of any race.
^dData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8b. Persons surviving >3 years after a diagnosis of HIV infection during 2011–2016, by year of diagnosis and selected characteristics—United States and 6 dependent areas
	Proportion survived >3 years
	No.	2011	2012	2013	2014	2015	2016
Gender
Male	191,275	0.94	0.94	0.94	0.95	0.95	0.95
Female	47,258	0.92	0.93	0.92	0.94	0.94	0.94
Transgender male-to-female^a	3,374	0.98	0.99	0.98	0.98	0.97	0.96
Transgender female-to-male^a	121	*	*	*	*	*	*
Additional gender identity^b	47	*	*	*	*	*	*
Age at diagnosis (yr)
13–24	53,914	0.99	0.99	0.99	0.99	0.99	0.99
25–34	74,622	0.97	0.97	0.97	0.97	0.98	0.98
35–44	49,035	0.94	0.95	0.94	0.95	0.95	0.95
45–54	41,296	0.89	0.90	0.90	0.91	0.92	0.91
≥55	23,208	0.79	0.81	0.80	0.81	0.82	0.83
Race/ethnicity
American Indian/Alaska Native	985	0.91	0.91	0.90	0.94	0.95	0.95
Asian	4,804	0.96	0.97	0.96	0.97	0.97	0.96
Black/African American	100,972	0.93	0.94	0.94	0.94	0.95	0.95
Hispanic/Latino^c	63,274	0.94	0.95	0.95	0.96	0.96	0.96
Native Hawaiian/other Pacific Islander	298	*	*	*	*	*	*
White	61,326	0.92	0.94	0.93	0.94	0.94	0.93
Multiracial	10,416	0.96	0.95	0.95	0.95	0.94	0.94
Transmission category^d
Male-to-male sexual contact	155,878	0.95	0.96	0.95	0.96	0.96	0.96
Injection drug use
Male	8,336	0.84	0.85	0.84	0.85	0.87	0.86
Female	6,529	0.88	0.89	0.88	0.89	0.91	0.89
Male-to-male sexual contact and injection drug use	9,329	0.95	0.94	0.94	0.95	0.95	0.94
Heterosexual contact^e
Male	20,939	0.89	0.89	0.89	0.91	0.90	0.91
Female	40,652	0.93	0.94	0.93	0.94	0.95	0.95
Region of residence
Northeast	40,880	0.94	0.94	0.94	0.95	0.95	0.95
Midwest	31,265	0.95	0.95	0.94	0.95	0.95	0.95
South	120,894	0.93	0.94	0.94	0.94	0.95	0.95
West	45,081	0.94	0.95	0.94	0.95	0.95	0.95
U.S. dependent areas	3,955	0.86	0.88	0.86	0.89	0.90	0.88
Total^f	242,075	0.93	0.94	0.94	0.95	0.95	0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cHispanic/Latino persons can be of any race.
^dData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8c. Persons surviving >3 years after a diagnosis of HIV infection during 2011–2016, by year of diagnosis and area of residence—United States and 6 dependent areas
	Proportion survived >3 years
Area of residence	No.	2011	2012	2013	2014	2015	2016
Alabama	3,942	0.93	0.93	0.93	0.92	0.94	0.95
Alaska	173	*	*	*	*	*	*
Arizona	4,003	0.93	0.92	0.94	0.96	0.94	0.94
Arkansas	1,638	0.91	0.96	0.92	0.92	0.93	0.96
California	29,538	0.94	0.95	0.94	0.95	0.96	0.96
Colorado	2,208	0.95	0.97	0.97	0.95	0.95	0.95
Connecticut	1,772	0.93	0.95	0.94	0.96	0.99	0.98
Delaware	689	0.94	0.93	0.96	0.96	0.97	0.94
District of Columbia	2,789	0.95	0.96	0.97	0.96	0.96	0.96
Florida	26,873	0.92	0.93	0.93	0.94	0.94	0.95
Georgia	14,995	0.93	0.93	0.94	0.95	0.94	0.95
Hawaii	546	*	*	*	*	*	*
Idaho	203	*	*	*	*	*	*
Illinois	9,339	0.94	0.96	0.95	0.95	0.96	0.96
Indiana	3,003	0.94	0.94	0.93	0.94	0.94	0.95
Iowa	697	0.95	0.93	0.92	0.93	0.97	0.95
Kansas^a	864	0.96	0.95	0.90	0.96	0.94	0.95
Kentucky	2,038	0.92	0.93	0.92	0.92	0.95	0.93
Louisiana	6,707	0.93	0.92	0.94	0.94	0.94	0.95
Maine	293	*	*	*	*	*	*
Maryland	7,456	0.94	0.95	0.94	0.96	0.96	0.96
Massachusetts^a	3,904	0.96	0.98	0.97	0.97	0.97	0.95
Michigan	4,549	0.93	0.95	0.93	0.95	0.95	0.95
Minnesota	1,812	0.96	0.97	0.93	0.95	0.97	0.98
Mississippi^a	2,829	0.91	0.94	0.92	0.93	0.93	0.93
Missouri	2,950	0.95	0.95	0.94	0.96	0.96	0.95
Montana	115	*	*	*	*	*	*
Nebraska	479	*	*	*	*	*	*
Nevada^a	2,585	0.92	0.92	0.94	0.95	0.95	0.95
New Hampshire	227	*	*	*	*	*	*
New Jersey	7,207	0.91	0.93	0.91	0.94	0.95	0.95
New Mexico	789	0.95	0.97	0.94	0.93	0.91	0.99
New York	19,385	0.94	0.95	0.95	0.95	0.96	0.95
North Carolina	7,940	0.94	0.94	0.95	0.95	0.94	0.95
North Dakota^a	127	*	*	*	*	*	*
Ohio	5,905	0.95	0.95	0.95	0.94	0.94	0.93
Oklahoma	1,834	0.91	0.94	0.92	0.94	0.94	0.95
Oregon	1,404	0.94	0.93	0.96	0.93	0.96	0.95
Pennsylvania	7,545	0.93	0.93	0.93	0.93	0.94	0.96
Rhode Island	473	*	*	*	*	*	*
South Carolina	4,305	0.93	0.95	0.93	0.93	0.94	0.94
South Dakota	173	*	*	*	*	*	*
Tennessee	4,661	0.94	0.92	0.92	0.93	0.93	0.95
Texas	26,242	0.94	0.94	0.94	0.95	0.95	0.95
Utah	711	0.96	0.95	0.94	0.98	0.97	0.94
Vermont^a	74	*	*	*	*	*	*
Virginia	5,496	0.93	0.94	0.95	0.96	0.97	0.95
Washington	2,720	0.94	0.97	0.95	0.95	0.98	0.94
West Virginia	460	*	*	*	*	*	*
Wisconsin	1,367	0.95	0.96	0.95	0.94	0.98	0.97
Wyoming	86	*	*	*	*	*	*
Subtotal	238,120	0.94	0.94	0.94	0.95	0.95	0.95
U.S. dependent areas
American Samoa	0	*	*	*	*	*	*
Guam	22	*	*	*	*	*	*
Northern Mariana Islands	6	*	*	*	*	*	*
Puerto Rico	3,807	0.86	0.88	0.86	0.89	0.90	0.88
Republic of Palau	4	*	*	*	*	*	*
U.S. Virgin Islands^a	116	*	*	*	*	*	*
Subtotal	3,955	0.86	0.88	0.86	0.89	0.90	0.88
Total	242,075	0.93	0.94	0.94	0.95	0.95	0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.

^aData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 8d. Persons with HIV surviving >3 years after stage 3 (AIDS) classification during 2011–2016, by year and selected characteristics—United States
	Proportion survived >3 years
	No.	2011	2012	2013	2014	2015	2016
Gender
Male	96,765	0.86	0.87	0.86	0.85	0.86	0.86
Female	31,622	0.85	0.85	0.84	0.84	0.84	0.86
Transgender male-to-female^a	1,494	0.94	0.94	0.92	0.92	0.90	0.92
Transgender female-to-male^a	40	*	*	*	*	*	*
Additional gender identity^b	16	*	*	*	*	*	*
Age at diagnosis (yr)
13–24	11,735	0.96	0.95	0.96	0.94	0.95	0.96
25–34	32,052	0.92	0.93	0.92	0.92	0.92	0.93
35–44	32,924	0.89	0.89	0.89	0.88	0.88	0.88
45–54	33,380	0.83	0.83	0.83	0.83	0.83	0.83
≥55	19,846	0.70	0.72	0.71	0.68	0.70	0.71
Race/ethnicity
American Indian/Alaska Native	508	*	*	*	*	*	*
Asian	1,910	0.92	0.93	0.91	0.91	0.91	0.89
Black/African American	59,282	0.85	0.86	0.85	0.84	0.86	0.86
Hispanic/Latino^c	29,616	0.89	0.90	0.89	0.88	0.88	0.90
Native Hawaiian/other Pacific Islander	123	*	*	*	*	*	*
White	31,428	0.85	0.84	0.84	0.83	0.82	0.82
Multiracial	7,070	0.89	0.88	0.88	0.86	0.85	0.84
Transmission category^d
Male-to-male sexual contact	69,623	0.88	0.89	0.88	0.87	0.87	0.88
Injection drug use
Male	7,270	0.77	0.77	0.75	0.75	0.74	0.74
Female	5,854	0.80	0.79	0.79	0.77	0.78	0.79
Male-to-male sexual contact and injection drug use	6,335	0.87	0.86	0.84	0.85	0.84	0.84
Heterosexual contact^e
Male	14,452	0.83	0.83	0.82	0.82	0.83	0.83
Female	25,172	0.86	0.86	0.85	0.85	0.86	0.87
Region of residence
Northeast	23,871	0.87	0.88	0.87	0.86	0.87	0.87
Midwest	16,626	0.88	0.88	0.88	0.87	0.87	0.87
South	67,513	0.85	0.85	0.85	0.84	0.84	0.85
West	21,927	0.87	0.87	0.87	0.86	0.85	0.86
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	105,340	0.87	0.87	0.87	0.85	0.86	0.86
Metropolitan areas (pop. 50,000–499,999)	15,221	0.84	0.84	0.84	0.82	0.84	0.83
Nonmetropolitan areas (pop. <50,000)	8,707	0.83	0.83	0.83	0.81	0.81	0.85
Total^f	129,937	0.86	0.86	0.86	0.85	0.85	0.86

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cHispanic/Latino persons can be of any race.
^dData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8e. Persons with HIV surviving >3 years after stage 3 (AIDS) classification during 2011–2016, by year of diagnosis and selected characteristics—United States and 6 dependent areas
	Proportion survived >3 years
	No.	2011	2012	2013	2014	2015	2016
Gender
Male	98,423	0.86	0.86	0.86	0.85	0.85	0.86
Female	32,275	0.85	0.85	0.84	0.84	0.84	0.86
Transgender male-to-female^a	1,499	0.95	0.94	0.92	0.92	0.91	0.92
Transgender female-to-male^a	40	*	*	*	*	*	*
Additional gender identity^b	16	*	*	*	*	*	*
Age at diagnosis (yr)
13–24	11,865	0.96	0.95	0.96	0.94	0.95	0.96
25–34	32,431	0.92	0.92	0.92	0.92	0.92	0.93
35–44	33,548	0.89	0.89	0.89	0.87	0.88	0.88
45–54	34,098	0.82	0.83	0.83	0.83	0.82	0.83
≥55	20,311	0.70	0.71	0.71	0.68	0.70	0.71
Race/ethnicity
American Indian/Alaska Native	508	*	*	*	*	*	*
Asian	1,917	0.91	0.93	0.91	0.91	0.91	0.89
Black/African American	59,325	0.85	0.86	0.85	0.84	0.86	0.86
Hispanic/Latino^c	31,861	0.88	0.89	0.88	0.87	0.87	0.89
Native Hawaiian/other Pacific Islander	132	*	*	*	*	*	*
White	31,437	0.85	0.84	0.84	0.83	0.82	0.82
Multiracial	7,073	0.89	0.88	0.88	0.86	0.85	0.84
Transmission category^d
Male-to-male sexual contact	70,287	0.88	0.89	0.88	0.87	0.87	0.88
Injection drug use
Male	7,705	0.76	0.76	0.75	0.74	0.73	0.74
Female	5,987	0.80	0.79	0.79	0.77	0.77	0.79
Male-to-male sexual contact and injection drug use	6,446	0.86	0.86	0.84	0.85	0.84	0.84
Heterosexual contact^e
Male	14,891	0.82	0.83	0.82	0.81	0.83	0.83
Female	25,675	0.86	0.86	0.85	0.85	0.86	0.87
Region of residence
Northeast	23,871	0.87	0.88	0.87	0.86	0.87	0.87
Midwest	16,626	0.88	0.88	0.88	0.87	0.87	0.87
South	67,513	0.85	0.85	0.85	0.84	0.84	0.85
West	21,927	0.87	0.87	0.87	0.86	0.85	0.86
U.S. dependent areas	2,316	0.74	0.74	0.77	0.74	0.72	0.74
Total^f	132,253	0.86	0.86	0.86	0.85	0.85	0.86

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown.

^a“Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^cHispanic/Latino persons can be of any race.
^dData have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and include transgender persons.
^eHeterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIncludes persons whose infection were attributed to hemophilia, blood transfusion, perinatal exposure, or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8f. Persons with HIV surviving >3 years after stage 3 (AIDS) classification during 2011–2016, by year of diagnosis and area of residence—United States and 6 dependent areas
	Proportion survived >3 years
Area of residence	No.	2011	2012	2013	2014	2015	2016
Alabama	2,253	0.84	0.80	0.82	0.81	0.84	0.85
Alaska	107	*	*	*	*	*	*
Arizona	1,889	0.86	0.82	0.84	0.85	0.81	0.83
Arkansas	784	0.79	0.86	0.87	0.77	0.84	0.89
California	13,939	0.88	0.87	0.87	0.85	0.86	0.86
Colorado	1,177	0.87	0.91	0.89	0.88	0.84	0.87
Connecticut	1,174	0.90	0.89	0.88	0.88	0.93	0.91
Delaware	472	*	*	*	*	*	*
District of Columbia	1,526	0.88	0.88	0.88	0.82	0.85	0.90
Florida	15,538	0.82	0.85	0.82	0.82	0.83	0.85
Georgia	8,258	0.85	0.85	0.86	0.86	0.87	0.87
Hawaii	286	*	*	*	*	*	*
Idaho	118	*	*	*	*	*	*
Illinois	4,793	0.88	0.89	0.89	0.86	0.87	0.88
Indiana	1,575	0.86	0.87	0.85	0.86	0.84	0.84
Iowa	415	*	*	*	*	*	*
Kansas^a	446	*	*	*	*	*	*
Kentucky	1,018	0.86	0.83	0.81	0.84	0.82	0.86
Louisiana	3,884	0.83	0.83	0.84	0.82	0.84	0.86
Maine	138	*	*	*	*	*	*
Maryland	4,387	0.88	0.87	0.87	0.88	0.87	0.85
Massachusetts^a	2,070	0.90	0.93	0.91	0.90	0.92	0.89
Michigan	2,460	0.87	0.86	0.85	0.88	0.83	0.87
Minnesota	1,016	0.90	0.91	0.91	0.90	0.91	0.96
Mississippi^a	1,870	0.86	0.82	0.84	0.82	0.83	0.83
Missouri	1,578	0.89	0.91	0.87	0.90	0.88	0.86
Montana	71	*	*	*	*	*	*
Nebraska	284	*	*	*	*	*	*
Nevada^a	1,332	0.80	0.80	0.87	0.83	0.83	0.83
New Hampshire	118	*	*	*	*	*	*
New Jersey	4,200	0.81	0.85	0.84	0.86	0.85	0.85
New Mexico	422	*	*	*	*	*	*
New York	11,543	0.88	0.88	0.88	0.86	0.86	0.88
North Carolina	4,422	0.85	0.86	0.87	0.83	0.83	0.83
North Dakota^a	63	*	*	*	*	*	*
Ohio	3,115	0.91	0.86	0.89	0.85	0.89	0.85
Oklahoma	983	0.81	0.81	0.76	0.84	0.87	0.87
Oregon	810	0.86	0.88	0.88	0.86	0.89	0.86
Pennsylvania	4,305	0.86	0.88	0.85	0.86	0.86	0.88
Rhode Island	279	*	*	*	*	*	*
South Carolina	2,655	0.85	0.88	0.84	0.82	0.85	0.84
South Dakota	109	*	*	*	*	*	*
Tennessee	2,632	0.83	0.85	0.85	0.83	0.83	0.85
Texas	13,825	0.87	0.86	0.86	0.85	0.85	0.86
Utah	347	*	*	*	*	*	*
Vermont^a	44	*	*	*	*	*	*
Virginia	2,723	0.85	0.84	0.90	0.84	0.85	0.87
Washington	1,363	0.86	0.92	0.91	0.89	0.86	0.88
West Virginia	283	*	*	*	*	*	*
Wisconsin	772	0.89	0.91	0.85	0.82	0.91	0.86
Wyoming	66	*	*	*	*	*	*
Subtotal	129,937	0.86	0.86	0.86	0.85	0.85	0.86
U.S. dependent areas
American Samoa	0	*	*	*	*	*	*
Guam	14	*	*	*	*	*	*
Northern Mariana Islands	5	*	*	*	*	*	*
Puerto Rico	2,221	0.75	0.74	0.76	0.73	0.72	0.74
Republic of Palau	2	*	*	*	*	*	*
U.S. Virgin Islands^a	74	*	*	*	*	*	*
Subtotal	2,316	0.74	0.74	0.77	0.74	0.72	0.74
Total	132,253	0.86	0.86	0.86	0.85	0.85	0.86

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification.
Data exclude persons whose month of diagnosis or month of death is unknown.

^aData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2019.

Table 9a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2019, among persons aged ≥16 years, by selected characteristics—United States
	No. prescribed PrEP^a	No. with PrEP indications^b	PrEP coverage^c (%)
Sex at birth
Male	262,360	989,200	26.5
Female	21,955	227,010	9.7
Age (yr)
16–24	38,316	246,290	15.6
25–34	116,012	434,680	26.7
35–44	66,005	238,470	27.7
45–54	38,718	173,420	22.3
≥55	25,413	123,350	20.6
Race/ethnicity^d
Black/African American	38,284	468,540	8.2
Hispanic/Latino^e	43,812	312,820	14.0
Other	11,953	131,180	9.1
White	190,415	300,650	63.3
Total	284,464	1,216,210	23.4

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

^aEstimated using data from IQVIA pharmacy database reported through September 2020 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
^bEstimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2019 PrEP coverage data.
^cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^dRace/ethnicity data were only available for <40% of persons prescribed PrEP in 2019. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
^eHispanic/Latino persons can be of any race.

Table 9b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2019, among persons aged ≥16 years, by area of residence—United States and Puerto Rico
Area of residence	No. prescribed PrEP^a	No. with PrEP indications^b	PrEP coverage^c (%)
Alabama	1,907	11,020	17.3
Alaska	236	1,780	13.3
Arizona	4,825	25,780	18.7
Arkansas	794	5,130	15.5
California	43,952	165,030	26.6
Colorado	4,434	25,120	17.7
Connecticut	2,805	9,560	29.3
Delaware	488	4,400	11.1
District of Columbia	6,077	12,950	46.9
Florida	22,439	125,330	17.9
Georgia	8,999	39,030	23.1
Hawaii	857	4,360	19.7
Idaho	487	4,790	10.2
Illinois	17,190	55,860	30.8
Indiana	3,097	22,170	14.0
Iowa	1,473	4,760	30.9
Kansas	944	5,060	18.7
Kentucky	1,669	12,990	12.8
Louisiana	4,221	15,920	26.5
Maine	658	3,950	16.7
Maryland	5,218	27,300	19.1
Massachusetts	10,212	24,900	41.0
Michigan	4,552	29,570	15.4
Minnesota	4,317	21,720	19.9
Mississippi	959	4,530	21.2
Missouri	3,634	18,370	19.8
Montana	272	2,290	11.9
Nebraska	637	2,180	29.2
Nevada	2,266	11,390	19.9
New Hampshire	656	3,020	21.7
New Jersey	5,955	25,280	23.6
New Mexico	1,100	6,800	16.2
New York	36,285	72,640	50.0
North Carolina	5,671	32,490	17.5
North Dakota	202	1,520	13.3
Ohio	6,393	40,320	15.9
Oklahoma	1,230	11,030	11.2
Oregon	3,396	19,750	17.2
Pennsylvania	10,546	36,490	28.9
Puerto Rico	348	9,700	3.6
Rhode Island	1,133	3,880	29.2
South Carolina	1,788	10,390	17.2
South Dakota	151	910	16.6
Tennessee	4,020	22,460	17.9
Texas	23,898	123,790	19.3
Utah	2,029	6,840	29.7
Vermont	348	1,060	32.8
Virginia	4,686	31,430	14.9
Washington	10,864	40,050	27.1
West Virginia	610	5,250	11.6
Wisconsin	2,678	12,980	20.6
Wyoming	99	890	11.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^aEstimated using 2019 data from IQVIA pharmacy database reported through September 2020 and based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
^bEstimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2019 PrEP coverage data.
^cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 10a. Perinatally acquired HIV infection, by year of birth and mother’s race/ethnicity, 2015–2019—United States
	2015		2016		2017		2018		2019
Race/ethnicity^a	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate
Black/African American	40	6.8	31	5.5	27	4.8	21	3.8	16	2.9
Hispanic/Latino^b	8	0.9	11	1.2	5	0.6	6	0.7	5	0.6
White	9	0.4	2	0.1	5	0.3	6	0.3	5	0.3
Other	6	2.0	7	1.9	6	1.6	4	1.1	3	0.8
Total	63	1.6	51	1.3	43	1.1	37	1.0	29	0.8

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Please use caution when interpreting perinatally acquired HIV infection numbers.

^aLive-birth data reflect race/ethnicity of the infant’s mother.
^bHispanic/Latino persons can be of any race.

Table 10b. Perinatally acquired HIV infection among persons born in the United States, by year of birth and mother’s race/ethnicity, 2015–2019—United States
	2015		2016		2017		2018		2019
Race/ethnicity^a	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate
Black/African American	34	5.8	28	5.0	24	4.3	19	3.4	16	2.9
Hispanic/Latino^b	8	0.9	10	1.1	5	0.6	6	0.7	5	0.6
White	8	0.4	2	0.1	5	0.3	6	0.3	5	0.3
Other	5	1.7	6	1.6	5	1.3	4	1.1	3	0.8
Total	55	1.4	46	1.2	39	1.0	35	0.9	29	0.8

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Please use caution when interpreting perinatally acquired HIV infection numbers.

^aLive-birth data reflect race/ethnicity of the infant’s mother.
^bHispanic/Latino persons can be of any race.

Table 11. Monitoring Ending the HIV Epidemic (EHE) indicators by using data from the National HIV Surveillance System (NHSS) and other reporting systems
	Year
Indicator	2017^a	2018	2019
Reduce the estimated number of new HIV infections by 90 percent^a	37,000	36,200	34,800
Increase the percentage of people living with HIV who know their serostatus to at least 95 percent (Knowledge of HIV status)^b	85.8	86.3	86.7
Reduce the number of new HIV diagnoses by 90 percent^c	38,351	37,382	36,337
Increase the percentage of persons with newly diagnosed HIV infection linked to HIV medical care within one month of diagnosis to at least 95 percent	77.8	80.2	81.3
Increase the percentage of persons with diagnosed HIV infection who are virally suppressed to at least 95 percent	63.1	64.7	65.5
Increase the percentage of the estimated number of persons with indications for PrEP who have been classified as having been prescribed PrEP to at least 50% (PrEP coverage)^d	13.2	18.6	23.4

Abbreviations: n/a, not available; PrEP, preexposure prophylaxis [footnotes only].

Note: Information on Ending the HIV Epidemic in the United States can be found at https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overviewexternal icon. For data on EHE Phase I jurisdictions, see https://www.cdc.gov/hiv/pdf/library/reports/ehe-core-indicators/cdc-hiv-ehe-core-indicators-2019.pdf pdf icon[PDF – 1 MB].

^aBaseline data for EHE indicators, published at: https://www.cdc.gov/hiv/pdf/library/reports/ehe-core-indicators/cdc-hiv-ehe-core-indicators-2019.pdf pdf icon[PDF – 1 MB]. Baseline PrEP data updated and published at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-2/index.html.
^b CDC. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental Report 2021;26(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2021.
^c Adults and adolescents only. CDC. HIV Surveillance Report, 2019; vol. 32. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2021.
^d PrEP coverage, reported as a percentage, was calculated as the number of persons classified as having been been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 12. Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2020—50 states, District of Columbia, and U.S. dependent areas
	CD4 count (cells/µL) or CD4 percentage			Viral load
	Lab reporting required^a	Reportable level^b	Lab reporting required^a	Reportable level^b
Alabama	Yes	All values	Yes	Any result
Alaska	Yes	All values	Yes	Any result
American Samoa	No	—	No	—
Arizona	Yes	All values	Yes	Any result
Arkansas	Yes	All values	Yes	Any result
California	Yes	All values	Yes	Any result
Colorado	Yes	All values	Yes	Any result
Connecticut	Yes	All values	Yes	Any result
Delaware	Yes	All values	Yes	Any result
District Columbia	Yes	All values	Yes	Any result
Florida	Yes	All values	Yes	Any result
Georgia	Yes	All values	Yes	Any result
Guam	Yes	All values	Yes	Any result
Hawaii	Yes	All values	Yes	Any result
Idaho	Yes	<200 or <14%	Yes	Detectable
Illinois	Yes	All values	Yes	Any result
Indiana	Yes	All values	Yes	Any result
Iowa	Yes	All values	Yes	Any result
Kansas	Yes	All values	Yes	Any result
Kentucky	Yes	All values	Yes	Any result
Louisiana	Yes	All values	Yes	Any result
Maine	Yes	All values	Yes	Any result
Marshall Islands	No	—	No	—
Maryland	Yes	All values	Yes	Any result
Massachusetts	Yes	All values	Yes	Any result
Michigan	Yes	All values	Yes	Any result
Minnesota	Yes	All values	Yes	Any result
Mississippi	Yes	All values	Yes	Any result
Missouri	Yes	All values	Yes	Any result
Montana	Yes	All values	Yes	Any result
Nebraska	Yes	All values	Yes	Any result
Nevada	Yes	All values	Yes	Any result
New Hampshire	Yes	All values	Yes	Any result
New Jersey	Yes	<200 or <14%	Yes	Any result
New Mexico	Yes	All values	Yes	Any result
New York	Yes	All values	Yes	Any result
North Carolina	Yes	All values	Yes	Any result
North Dakota	Yes	All values	Yes	Any result
Northern Mariana Islands	No	—	No	—
Ohio	Yes	All values	Yes	Any result
Oklahoma	Yes	All values	Yes	Any result
Oregon	Yes	All values	Yes	Any result
Pennsylvania	Yes	All values	Yes	Any result
Puerto Rico	Yes	All values	Yes	Any result
Republic of Palau	No	—	No	—
Rhode Island	Yes	All values	Yes	Any result
South Carolina	Yes	All values	Yes	Any result
South Dakota	Yes	All values	Yes	Any result
Tennessee	Yes	All values	Yes	Any result
Texas	Yes	All values	Yes	Any result
U.S. Virgin Islands	Yes	<200 or <14%	Yes	Detectable
Utah	Yes	All values	Yes	Any result
Vermont	Yes	All values	Yes	Any result
Virginia	Yes	All values	Yes	Any result
Washington	Yes	All values	Yes	Any result
West Virginia	Yes	All values	Yes	Any result
Wisconsin	Yes	All values	Yes	Any result
Wyoming	Yes	All values	Yes	Any result

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage.

Note: Information on Ending the HIV Epidemic: A Plan for America can be found at https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overviewexternal icon. For data on EHE Phase I jurisdictions, see https://www.cdc.gov/hiv/pdf/library/reports/ehe-core-indicators/cdc-hiv-ehe-core-indicators-2019.pdf pdf icon[PDF – 1 MB].

^a Laws, regulations, or statutes in most areas require laboratories to report, but in some instances the language is not specific.
^b Level at which CD4 or viral load reporting is required by laws, regulations, or statutes.

Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2019: Tables

Download the Full Report pdf icon[PDF – 17 MB]

Report Contents

Other Reports